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Abstract
Resistance to conventional chemotherapies, especially to anti-cancer agents, is rapidly becoming a
global pandemic. Mutations, in combination with genetic instabilities, play an important role in
the molecular heterogeneity of cancerous cells that display resistance to chemotherapeutic drugs.
Currently, mechanisms involved in drug resistance phenotype resulting from the interaction of a
tumour and anti-cancer agents are not fully understood. In this dissertation, we propose two new
dynamical models for the interaction between a tumour and a chemotherapeutic drug. Our focus
is only on resistance which is caused by random genetic point mutations. The models consist of
coupled systems of ordinary and partial differential equations. Tumour cells are divided into two
classes, namely; sensitive and resistant cells. We determine the equilibrium points of the model
equations and investigate their stability. In the first instance, after reviewing the basic modelling
assumptions and main results found in the mathematical modelling literature on drug resistance, we
present the ordinary differential equation (ODE) model. To account for spatial growth effects, we then
extend the model to a partial differential equation (PDE) model that describes the local interaction
of the tumour with the anti-cancer agent through convection, reaction and diffusion processes. Some
analytical solutions of the PDE model that are comparable to those found in the literature are
obtained. One novel outcome of the models in this dissertation is the qualitative demonstration
of the possible success of the therapy for certain initial conditions, number of sensitive cells and
their interaction with the chemotherapeutic drug. Parameter sensitivity analysis is carried out to
determine the influence of each individual parameter in the model. For all the models, numerical
solutions which showed the effect of therapeutic agents on the growth and spread of the tumour cells,
subject to evolving drug resistance phenomenon, were attained and presented here.
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Cancer is a major global health problem and a leading cause of deaths worldwide [6]. According
to the International Agency for Research on Cancer, there were 12.7 million new cases of cancer in
2008. The global cancer burden is expected to double to 21.4 million cases with the corresponding
deaths of 13.5 million by 2030 [7]. Some cancers can be treated successfully even with current medical
treatment options [8, 9]. However, to date, there is still no cure for most cancers [10, 11].
Cancer is generally defined as an unrestrained growth of abnormal cells in any part of the body.
There are various distinct types of cancers, which can change substantially in their phenotype (the
appearance of a cancerous cell resulting from its interaction with a surrounding environment) and
response to treatment. Normal cells have regulatory mechanisms that govern cell proliferation (i.e
a cellular division or increase in number), differentiation (the degree of tumours capacity in relation
to invasiveness and mortality), survival and death of the individual cells. Cancer cells, on the other
hand, behave quite differently. Cancer can occur when there is either a fast unbounded growth of
abnormal cells or cells have lost their ability to die; thereby resulting in the formation of a mass called
a tumour. Tumours can be classified in two ways, namely benign or malignant tumours. A benign
tumour usually remains confined to its tissue of origin. Benign tumours may be harmful due to their
interference in body regulatory mechanisms that accompany the cellular proliferation, growth and
death of individual cells. So they can be harmful, although they are usually considered less dangerous
and or less invasive than malignant tumours. A malignant tumour is one that can metastasize (i.e
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invade the surrounding tissues, and spread to other distant body sites). The metastatic tumours
initially grow locally in the primary tissue before they can spread to other distant sites through the
bloodstream and the lymphatic system.
Figure 1.1: The stages of tumour metastasis, Source [1].
Figure 1.1 gives a summary of the metastatic processes. Step (1) illustrates the state at which the
tumour grows at its primary site, (2) represents the state at which the tumour has broken away
from the original site and entered the bloodstream or lymphatic system, (3) shows the cancerous
cells travelling through the bloodstream or lymphatic system to other parts of the body, (4) denotes
the state at which the tumour escapes the bloodstream or lymphatic system and breaks into the
nearby tissue, and finally (5) represents the state at which the tumour has now invaded the nearby
tissue and started to grow into a new tumour [1]. Metastasis has been reported as the most frequent
cause of cancer death, therefore, systemic or targeted therapies are required to improve patients
health [12–16].
There are many causes of cancer that have been identified to date, including excessive exposure
to sunlight, drinking excessive alcohol, exposure to certain chemicals and genetic differences [17].
However, many of the cancer causing agents are still unknown [18]. In the case of known cancer types,
there exist a considerable number of treatment options for patients including chemotherapy [19–24],
surgery [25], immunotherapy [6, 20, 26–32], radiotherapy [33, 34], anti-angiogenesis [8, 33, 35], and
oncolytic virus therapy (virotherapy) [36,37]. Treatment usually improves the patients quality of life
or brings about remission of the cancer [10,11]. However, mathematical and biological knowledge of
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these treatment modalities is still in its infancy.
The effectiveness of cancer treatment varies between patients and with the type of cancer. Some
cancers may remain undetectable for years, while others may grow and metastasize rapidly, and
cause death within a short period. Nevertheless, in as much as there are numerous distinct cancer
types, Hanahan and Weinberg [38] showed that, in their rapid cell growth, most human cancers have
six basic properties, to be specific:
(i) unbounded replicative potential,
(ii) insensitivity to growth-inhibitory signals,
(iii) tissue invasion and metastasis,
(iv) self-sufficiency in growth signals,
(v) evasion of programmed cell death, and finally
(vi) sustained angiogenesis (development of new blood vessels)
Conventional cancer treatments follow three principal regimens. Firstly surgery, may be appropriate
where the tumour is of a detectable size and is localized; that is, it is unlikely to have metastasized.
A second therapy option is radiotherapy, which uses radiation to kill the cancerous cells. However it
may cause a further problem of killing healthy surrounding tissues if tumour has metastasized. The
third option is chemotherapy, where cytotoxic drugs are used to invade the rapidly proliferating cells.
However, a major limitation of chemotherapy is that it also kills any normal healthy cells that also
have a rapid proliferation rate, such as those found in bone marrow [8]. Furthermore, despite great
advances in both biological and clinical understanding of cancer, there remain only a few cancer types
that are known to be sensitive to standard therapies and which are thus potentially curable. These
include many pediatric tumours, several hematological cancers and germ cell tumours such as those
found in the testis [9]. Therefore, despite great advances in both biological and clinical understanding
of drug sensitivity, drug-resistant tumour populations remain a major challenge for both scientific
and clinical researchers [9, 39–43].
Resistance to a single chemotherapeutic drug has been reported in many mathematical, biological
and oncological studies [5, 44–49]. Although many tumour cells may be intrinsically resistant to
chemotherapy, such resistance being caused by mutant genes, in some cases, a tumour may also
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develop resistance to a chemotherapeutic agent later during therapy due to cell mutations in response
to signals from the micro-environment. This later development may then confer resistance to a specific
chemotherapeutic drug [43]. Examples of reported acquired drug resistance studies include breast
cancers that show a loss of estrogen receptor following the emergence of tamoxifen resistance [50];
the development of mutations that render chronic myelogenous leukemia (CML) cells resistance to
the drug imatinib [51], and non small cell lung cancer (NSCLC) resistance to the drug gefitimb [52].
With diverse underlying evolutionary mechanisms and pathways to drug resistance, the development
of tumour sub-populations, which modify the overall sensitivity of the drug sensitive cells, still remains
a problem in clinical oncology [46]. Due to drug resistance, there is a need for better understanding of
the roles played by various treatments modalities for the inhibition of tumour growth and metastasis.
This is an exceptionally difficult task since cancer cells are usually composed of cells that may be in
different phases of their cell cycle [10]. Furthermore, for any given type of cancer, the macroscopic
properties of the tumour may depend on the number of the cancer cells present at that instant. As a
result, mathematical modelling of malignant tumours faces challenges in terms of which parameters
to prioritise, because there are no consistent data about the properties of a given cancer [10, 20, 53].
In response to this challenge, mathematical models developed in this dissertation will provide a
theoretical description of dynamical systems concerned in the spread of cancerous cells. These models
will thus provide qualitative and quantitative understanding of the effects of various treatment options
on cancerous cells.
There are two major aims in this study. We seek to understand, and model, the biological aspects
of cancer that concern:
(i) cell population growth describing the production of offspring through cell proliferation, death
and local interaction between tumour cells and cancer anti-agents,
(ii) spatial distribution dynamics of the cell populations through reaction, convection and diffusion
which describe the random mobility of cells, and biological phenomenon which are involved in
the migration of cancer anti-agents towards tumour cells.
In particular, we aim to answer the following questions;
(a) How do tumour cells escape cancer drugs or treatment?
(b) What interventions can be implemented to reduce or minimise this escape?
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As a first approach to answering these questions, we develop deterministic mathematical models that;
(1) take into consideration the local population growth and reaction kinetics,
(2) model the dynamics of spatial distribution of the tumour sub-populations through reaction,
convection and diffusion,
(3) enhance our understanding of the effect of different interventions on the tumour cell sub-populations
through qualitative and numerical analyses.
1.2 A review of mathematical models for drug resistance
Along with biological and clinical research, many mathematical models have been developed to model
the development of drug resistance in cancer. Such mathematical models have the advantage over
clinical studies in that they provide significant insights into the dynamics of the drug resistance
before the model could be used in carrying out the clinical trials. Economically, this help to save
money that could be used to implement the dimly understood drug resistance phenomenon. Further,
conclusions from mathematical models could provide a valuable information to clinical researchers
to develop new trials with a more refined focus, and in some cases lead to new clinical trials [45].
In earlier studies [39–41], the evolution of drug resistance was identified as the major source of
failure in many chemotherapies. Mathematical models that take into account the undesirable effects
of drug-resistance can be found in [10, 11, 22, 41, 54–56] with succinct reviews published in [45, 46].
These studies range from deterministic to stochastic models, and from discrete (agent-based) to
continuum models. The models include those composed of ordinary differential equations (ODEs),
partial differential equations (PDEs), delayed differential equations (DDEs), and integro differential
equations (IDEs) [45,46].
In literature, there are mathematical models which consider the mechanism of genetic point mutations
and gene amplification. Gene amplification comes as a result of an overproduction of a particular gene
or genes. This means that larger portion of the genome would be replaced by copies of one gene, which,
in turn, confer resistance to a particular drug. By using branching stochastic processes, mathematical
models of drug resistance due to gene amplification were done in [57,58]. Point mutations are random
genetic changes that occur during cell division. The models of this type have been considered in
earlier works of Coldman and Goldie [5]. One novel feature of their model is that small tumours
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have a higher probability of not having drug resistance than large solid tumours. However, more
recent reports of stochastic models of point mutations are found in Komarova [54, 59]. By using
PDEs and probabilistic methods, Komarova [59] showed that the tumour pre-treatment phase is
more important in the development of drug resistance than the treatment phase. Further, Komarova
and Wodarz [54] showed, within the assumptions of their model, that using a combination of three
drugs with different specificities might overcome the problem of resistance. Another mathematical
report on genetic point mutations is by Iwasa et al [60] in which the branching processes were used
to compute the probability of resistance at the time the tumour is detected.
From these studies it can be seen that there has been considerable work on modelling of drug resistance
using stochastic processes. However, there is no enough information on the mechanisms of how do
cancer cells elude chemotherapy. It is nevertheless important to note that there are diverse underlying
evolutionary mechanisms and pathways to drug resistance. The development of the drug-resistant
tumour sub-populations which modify the overall sensitivity of the drug sensitive cells still remains a
major problem in clinical oncology [46]. Even though there are many treatment options available for
cancer patients, particularly in the early stages of the disease, the mortality rate is still high [61]. We
describe two particular ODE models here which will be used as starting points for our PDE model
which takes into account the effects of spatial dynamics of the tumour cells.
The first model we describe is the ODE model of Tomasetti and Levy [47] which describes the
probability of the development of drug resistance based on the number of cancerous cells at the time
of detection, the mutation rate and the turnover rate of the cancer cells. In their study, they first
distinguished two types of cells: the wild-type (cells that are sensitive to the drug), N(t), and the
cells that have undergone mutations and hence resistant to the drug, R(t). They further delineated
the branching processes that lead to drug resistance due to genetic point mutations. The model may
be described by the equationsN
′(t) = (L−D)N(t),
R′(t) = (L−D)R(t) + µN(t),
t ≤ t?
N
′(t) = (L−D −H)N(t),
R′(t) = (L−D −H)R(t) + µN(t),
t > t?
where N(t) is the number of wild-type cancer cells that are sensitive to a drug at time t, R(t) denotes
the cancer cells that have undergone mutations and are therefore resistant to the drug. L,D, µ denote
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the natural cell birth, death and mutation rates, respectively, while H denotes the drug-induced death
rate. An interesting finding from this model is that the levels of resistance, before the start of the
treatment and present at some given time afterwards, always depends on the turnover rate D/L,
regardless of the number of chemotherapeutic drugs used simultaneously in the treatment [8].
The mathematical model by Jackson and Byrne [48] played an important role in the development of
further mathematical models for drug resistance in solid tumours. Their spatially- dependant mathe-
matical model considered the response of vascular tumours and drug resistance to chemotherapeutic
treatment. In that study, two tumour cell types are distinguished with respect to their responsiveness
to a chemotherapeutic agent: a rapidly dividing population, p(r, t), which is highly susceptible to the
drug, and the other population, q(r, t), which has lower drug susceptibility. They further assumed
that the tumour spheroid expands or shrinks at a rate which depends upon the balance between cell
growth and division, and cell death within the tumour, in which the latter state is being modified
by the presence of the drug. d(r, t) denotes a chemotherapeutic drug concentration at time t, and
u(r, t) presents a local cell velocity. The model is described by the following equations:
∂d
∂t
+∇ · (ud) = ∇ · (D(r)∇d) + Γ(r)(dB(t)− d)− λd, (1.1)
∂p
∂t
+∇ · (up) = Dp∆p+ Fp(p)− Cp(p, d), (1.2)
∂q
∂t
+∇ · (uq) = Dq∆q + Fq(q)− Cq(q, d), (1.3)
where D(r) and Γ(r) are radial diffusion and coefficient of blood-tissue transfer, respectively. λ and dB
are the respective drug decay and prescribed drug concentration in the tumour vasculature. Dp and
Dq are the constant random motility coefficients of the two types of tumour cells and Fp(p) and Fq(q)
are their respective net proliferation rates. The functions Cp(p, d) and Cq(q, d) represent the effect
of the chemotherapy on each tumour sub-population. This model illustrates how the vasculature
exchange would affect the tumour’s response to therapy. Using this model, Jackson and Byrne [48]
found that the spatially- dependent blood-tissue transfer gave rise to the largest reduction in tumour
volume as compared to no blood-tissue transfer and constant blood-tissue transfer. Furthermore,
when the tumour consisted of only sensitive cells, minimum tumour radius was determined. From
this model, it could be seen that while under certain conditions the drug resistant sub-population
could be eliminated, nevertheless, tumour re-growth is possible.
In this dissertation, we draw some important tumour modelling assumptions on previous studies,
such as those outlined above to develop new mathematical models of drug resistance which take into
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account the effects of genetic point mutations. We will use both ordinary and partial differential
equations. We will then use computational methods to solve these differential equations. The nu-
merical schemes used include a hybrid fourth and fifth order Runge-Kutta differential solvers such
as ode45 and pdepe solvers.
1.3 Steady states analysis
In mathematical analysis of biological systems, particularly in anti-cancer modelling, the study of the
equilibria of the system and stability analysis are important tasks because stability conditions usually
indicate the conditions where tumour eradication is feasible [62,63]. Furthermore, it is important to
note that the orbital portraits of one steady state may differ from those of nearby steady states [62].
Thus, any categorisation of the steady state must be local.
There are two methods of determining the stability of any system, namely graphical stability analysis
and linearisation stability analysis. Because the models are comprised of nonlinear ODEs, for the
purposes of this study, we use the linearisation stability analysis. In effect, linearisation simply means
that we approximate a function by a first-order Taylor series expansion about the steady state. If
the linearization is performed, then the nonlinear system behaves more like a linear system, which is
easy to determine its stability, in the neighbourhood of equilibrium point.
For the purpose of this study, we use the linearisation method and deduce the stability of each steady
state based on the Rough-Hurwitz stability criterion [62,64–66], as described below.
To illustrate the linearisation technique, consider a biological system that is described by three
differential equations. The derivatives about the equilibrium point are given as
dx
dt


































We re-write this system in matrix notation as



























where the matrix J is the Jacobian matrix of the system. We find the eigenvalues of the Jacobian
matrix in order to deduce the stability of the system via the Routh-Hurwitz stability criterion, as
will be shown in Section 2.4 and 2.6.
1.3.1 Rough-Hurwitz stability criterion
In a complex dynamical system, determination of the stability of the system may not be easy.
However, the Rough-Hurwitz criterion provides necessary and sufficient conditions for the stability of
a system with n state variables [62,64–66]. May [64] provides a full description of the Routh-Hurwitz
stability criterion based on m = 1, 2, . . . , 5 state variables. In brief, the criterion can be given as
follows. Suppose the characteristic polynomial associated with the Jacobian matrix of the system of
differential equations with n state variables is
P (γ) = γn + a1γ
n−1 + · · ·+ an−1γ + an, (1.5)
where the coefficients a1, a2, . . . , an are real constants. We define the Hurwitz matrices corresponding
to the number of the state variables as
H1 = (a1), H2 =
 a1 1
a3 a2





 , . . . , (1.6)
Hn =

a1 1 0 0 . . . 0
a3 a2 a1 1 . . . 0







0 0 0 0 . . . an

, (1.7)
with ai = 0 whenever j > n. If all the roots of the polynomial (1.5) are negative or have a negative
real part, then the determinants of the Hurwitz matrices, (1.6)− (1.7) are positive. That is,
det(Hi) > 0, i = 1, 2, . . . , n. (1.8)
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In summary, the Rough-Hurwitz stability criterion for n = 2, 3, 4 and 5 is
n = 2 : a1 > 0 and a2 > 0,
n = 3 : a1 > 0, a3 > 0 and a1a2 > a3,










(a1a4 − a5)(a1a2a3 − a23 − a21a4) > a5(a1a2 − a3)2 + a1a25

(1.9)
The proof of this criterion is given by Gantmacher [66] for n = 2. We use this criterion because the
models considered here have more then two state variable. If there is no drug in the tumour, then the
system (2.4) − (2.6) deduces to a system of two state variables. Thus the Rough-Hurwitz criterion
would be helpful in determining the stability of the system.
1.3.2 Dulac’s criterion
Dulac’s Criterion is an important theorem used to determine if the system of differential equations has
no periodic orbits [67]. This criterion would be vital for the models considered in this study because
the periodic orbits might show the condition at which a tumour eradication is feasible or not. This
means that after a chemotherapeutic drug has killed some sensitive cells, then other cells, possibly
the resistant cells, might bring cancer remission later or not. In this study, it is also important to
investigate if tumour eradication is possible under the constraints of the models considered in this
study.
Consider a smooth differential equation system
ẋ = f(x, y), (1.10)
ẏ = g(x, y). (1.11)
Dulac’s criterion states that if there is a smooth function B(x, y) defined on a simply connected
region Ω ⊂ Rn such that
∂
∂x
(B · f) + ∂
∂y
(B · g) (1.12)
is not identically zero and of a fixed sign on Ω, then the system (1.10) − (1.11) has no periodic
solution on Ω. The main disadvantage of Dulac’s criterion is that there is no systemic way of finding
the function B(x, y). For this reason, the method is not always possible to use. Consequently, instead,
we make use of the Poincaré-Bendixson theorem.
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1.3.3 Poincaré-Bendixson Theorem
Dulac’s criterion is useful for demonstrating the existence of periodic solutions. To show that it a
periodic solution exists, a necessary and sufficient condition is that the Poincaré-Bendixson theorem
is satisfied. We state, without proof, the Poincaré-Bendixson theorem that is useful for demonstrating
the existence of the limit cycle of the system of differential equations [68].
Theorem 1.3.1. Suppose there is a function f ⊂ C1(E), where E is an open subset of R2, and φ is
the solution of the system ẋ = f(x). If Ω is a non-empty compact ω-limit set of φ, and Ω does not
contain a rest point (i.e. stable equilibrium point), then Ω is a periodic orbit.
Corollary 1.3.4. This Corollary follows directly from Theorem 1.3.1. If E contains a periodic orbit
Γ of the system ẋ = f(x) and its interior U , then U contains at least one rest point of the system, [68].
In order to determine the stability of the ODE systems, developed in this dissertation, about any
steady state, we shall use the Rough-Hurwitz stability criterion. Additionally, to show the existence
of a globally asymptotic stable point, in Section 2.4.2, we will use the Dulac’s criterion and a corollary
of the Poincaré-Bendixson theorem to show that there exist no periodic solutions associated with the
models considered in this study.
1.4 Sensitivity analysis
The modelling of complex biological system involves estimation and analysis of model parameters.
However, as indicated above, understanding of the multi-drug–tumour system may be limited by
lack of values for parameters. This deficiency can be partially addressed through a technique called
sensitivity analysis (SA). SA investigates the relationship between particular model parameters and
the characteristics of the observable outcome; thus indicating some phenotypic behaviour of the
system under study [69]. SA can be utilised, not only for identification of the model parameters that
are highly correlated with the state variables, but also to help prioritise research on those essential
parameters [70], particularly where there is no available medical literature for some of the model
parameters. To be specific, we will here identify the parameters that are most influential in the
dynamical behaviour of our systems.
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1.4.1 Partial rank correlation coefficient
We use the partial rank correlation coefficient (PRCC) test, to determine the statistical significance
of the model parameters on the outcome of the state variables. In particular we consider those
model state variables that have a monotonic but non-linear behaviour [71, 72]. PRCC uses the
Latin hypercube sampling technique (LHS). To implement the LHS, we first generate a random
sample of N vectors in the parameter space using the Latin hypercube sampling. LHS attempts
to sample the whole parameter space by separating the bounded subsets of the parameter space
into N compartments and then choosing a random value in each compartment from a uniform
distribution [72, 73]. To perform this task, we first needed to write a Matlab code and use the
Matlab built-in function lhsdesign to generate a matrix of parameter values between 0 and 1. Each
parameter set needed to be rescaled by the tumour carrying capacity 5× 107, [74]. By letting M be
the resultant matrix of the lhsdesign, then, using the output of the LHS, we could generate a vector,
Y , where yi represents a model value at any time t using the given parameter value of i
th row of the
matrix M .
The first step in the implementation of PRCC test is to rank the transformed matrices, which take
M and Y as inputs and return the matrices M and Y with the same dimensions, in which each
column contains all the integers from 1 to N . Note that the ordering of the integers in M and Y
corresponds to ordering of the integer values in the original matrices, where a 1 in the kth column of
M corresponds to the position of the lowest value in the kth column of M , and N corresponds to the
highest value.
Utilising the rank transformed matrices, M and Y , we can now fit a linear regression model for each
of the parameters, say p̄k, defined as
p̄k = a0 + a1p1 + · · ·+ ak−1pk−1 + ak+1pk+1 + · · ·+ anpn, (1.13)
which expresses a selected parameter pk as a linear combination of all other model parameters.
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Ȳpk = b0 + b1p1 + · · ·+ bk−1pk−1 + bk+1pk+1 + · · ·+ bnpn, (1.15)













 , and X =
[
1, p1, p2, . . . , pn
]
. (1.16)
The values p̄k and Ȳpk , together with pk and Y , are used to compute the residuals, res(pk) = pk − p̄k
and res(Ypk) = Y − Ȳpk , between the two data sets. The correlation coefficients between res(pk) and
res(Ypk) are computed via the Matlab built-in function corrcoeff. These correlation coefficients are
the required results of the PRCC, and measure the strength of the relationship between the two
given parameters, or the degree of association between a given state variable and a given parameter.
A correlation coefficient value close to 1 indicates a strong positive linear relationship between the
given state variable and the parameter in question, whereas a negative correlation coefficient value
close to −1 shows a strong negative relationship between the state variable and the given parameter.
Therefore, the sign indicates the qualitative relationship between the state variable and the parameter




, then there is no linear relationship between
the state variable and the parameter in question. Thus, the parameters with large PRCC values
greater then 0.5 or less than −0.5 are the most important [75]. The PRCC test is applicable only
in mathematical models that have two or more parameters. This is true for the ODE models in this
study. The quantitative results of the sensitivity analysis are presented in Chapter 4.
1.5 Dissertation structure
The remainder of the dissertation comprises four chapters where the major contributions to the
chemotherapeutic modelling of drug resistance in cancer are presented. In particular, two new math-
ematical models describing the interactions between tumour cells and chemotherapeutic agent(s) are
presented.
In Chapter 2, two new compartmental models describing the interactions between tumour cells and
chemotherapeutic drug(s) are constructed. In order to model these interactions, the system of several
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ordinary differential equations that take into account the effects of drug resistance to one and then
two chemotherapeutic agents are constructed. The steady states and stability of the systems are
investigated. The fixed points are important since they highlight the system solutions that might
bring about cancer eradication or remission. The stable points are solutions that might bring about
effective disease control and prolong the quality of life, while unstable points are solutions of the
uncontrolled state (i.e the state that usually leads to metastasis).
In Chapter 3, to account for the spatial distribution dynamics of the tumour sub-populations, a partial
differential equation model is constructed. Some analytical solutions of this model are presented.
Model simulations and parameter sensitivity analysis of the ODE models is presented in Chapter 4.
Numerical simulations provide a plausible dynamical model behaviour and interactions of tumour
sub-populations and chemotherapeutics drugs. In Chapter 5, the overall conclusions from the studies
are brought together and discussed in the light of previously published work. This highlights some
further points for future research. In the Appendix, a glossary of relevant biological terms is given.
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Chapter 2
A two compartmental ODE model for
drug resistance
2.1 Introduction
The use of ordinary differential equations (ODEs) to model tumour growth has a long history in
cancer modelling, [24, 76–82]. See specifically the work of Tomasetti and Levy [47] described in the
previous chapter. While ODEs can capture many important features of cell divisions in large cell
populations they have the added advantage of being computationally easy to work with. Nevertheless,
using ODEs in cancer modelling requires a number of simplifying assumptions to represent a three-
dimensional tumour. Thus, identifying the constituent components in any biological system is a
vital step to ensure robust mathematical and computational analysis. In this regard, it is important
to note that within a single tumour, there are likely to be a number of sub-populations that could
each be characterised by different intrinsic growth rates and treatment susceptibilities [83]. Thus,
in order to monitor the growth of the tumour, it is vital to track the total number of cells within
it, while also keeping track of each sub-population within it [24, 84–86]. However, with biological
phenomena, it is often difficult to adequately delineate which tumour components are present in
the system because some components or processes may not be well understood. Nevertheless, many
biological phenomena involving time-evolved systems can be analysed using ODEs consisting of two
cell populations [33,47].
Furthermore, there are some mathematical models in which partial resistance, and its corresponding
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correlation to the amount of the drug present, have been addressed [49, 87]. In this chapter, we
develop a non cell-cycle specific system of ODEs that govern the development of tumour cells under
the intervention of chemotherapeutic drug(s). We give the criteria and theorems needed to show
stability and non-existence of periodic solutions. The numerical solutions of these system of equations
are given in Chapter 4.
2.2 Chemotherapeutic model formulation
As explained in the previous chapter, one of the defining attributes of malignant tumours is their
ability to metastasise [88]. Furthermore, human cancer cells may include a sub-population with an
intrinsic drug resistance. In this section we develop a mathematical model that considers the case
in which the tumour develops the resistance to a single chemotherapeutic drug due to genetic point
mutations. We have also considered a similar biological setting to that proposed by Goldie and
Goldman [5], where, even-though the malignant cancer cells are highly heterogeneous, the tumour
is viewed as a single compartmental population composed of two types of cell sub-populations. The
first sub-population group consists of rapidly proliferating cells that are highly susceptible to the
drug, S(t), and the second sub-group consists of the cells that are drug resistant, R(t). Thus:
N(t) = S(t) +R(t), (2.1)
where N(t) is the total number of the tumour cells at time t.
2.2.1 Model assumptions
As mentioned earlier, modelling of biological system requires a number of simplifications. Therefore,
in constructing the first ODE model the following assumptions were made:
(i) There is a logistic growth in both types of cells, when there is no drug in the tumour, and the
intrinsic growth rates are different. It is reasonable to assume different growth rates because,
in [46], it was found experimentally that the sensitive tumour cells usually grow faster than
the resistant cells. Furthermore, it has been shown that in lung cancer cells, resistant to the
chemotherapeutic drug, gemcitabine, are less invasive and grow slowly than their drug sensitive
counterparts [89].
16
(ii) The drug kills only the sensitive cells and has no effect on the resistant cell population.
(iii) Mutation happens in only one direction (i.e. during mitosis, one of the daughter cells mutates
to a resistant cell and not vice-versa). This is a standard assumption when modelling resistance
due to genetic point mutations, rather than resistance caused by gene amplification [47].
(iv) We assume that an interaction between the chemotherapeutic drug and the tumour cells follows
an exponential saturation kinetics as in [21]. This exponential form has been validated by [90]
for a reasonable number of chemotherapeutic drugs.
By distinguishing between only two types of tumour cells, the model variables are;
(a) D(t), the chemotherapeutic drug concentration at time t,
(b) S(t), the number of tumour cells that are sensitive to the drug at time t,
(c) R(t), the number of tumour cells that are resistant to the drug at time t.
The model parameters, λS and λR are the intrinsic growth rates of sensitive and resistant cells,
respectively. λD represents a drug decay rate, µ is the mutation rate coefficient resulting from cell
division. kS is the susceptibility coefficient of the sensitive cells to the drug, while k is the drug
saturation coefficient for the tumour. V (t) represents an external time dependent influx of the
chemotherapeutic drug, and θ is the limiting size, commonly called maximum carrying capacity of
the tumour.
With these parameters, we model the dynamics of the chemotherapeutic drug by the equation
dD(t)
dt
= V (t)− λDD, (2.2)
with the following baseline conditions:
D(t) =
0 if t = 0,Dc(t) if t > 0, (2.3)
where Dc(t) is the drug concentration in the tumour (which depends on the external influx V (t) and
the natural decay rate of the drug, λD,) at any time t. We assume that λD ≥ 0, with inclusion
of a mathematical limit state λD = 0 to represent a situation of having no chemotherapeutic drug
decay in the tumour. We have assumed that, initially at time t = 0, there is no drug in the tumour,
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so D(0) = 0, as in Krabs and von Wolfersdorf [91]. We have further assumed that the amount of
the chemotherapeutic drug entering the patient is bounded above, that is 0 ≤ V (t) ≤ Vmax(t), in
accordance with [19,24,91–93].
During chemotherapy, the basic growth kinetics of the tumour cells is usually perturbed by the
intravenous infusion of the cytotoxic agent at any time t [94]. Thus, we write our full model as
dD(t)
dt

















The corresponding initial conditions for the system (2.4)− (2.6), given by the initial drug concentra-
tion, the initial number of the sensitive and resistant cells, are
D(0) = 0, S(0) = S0, R(0) = R0, (2.7)
where each of the above initial values is non-negative. In order to determine the effects of the
chemotherapeutic drug, we have assumed that there is at least one tumour cell that is sensitive to
the drug at the start of the therapy. The domain of the model is [0, Tf ], where Tf ∈ R+ is a fixed time
of chemotherapy. In the second equation (2.5), the last term denotes the loss term (i.e the sensitive
cells death due to the presence of the drug at the tumour site.) In both tumour sub-populations,
equations (2.5) and (2.6), the first term denotes the logistic growth of tumour cells. This model
obeys the growth laws on a finite interval [0, θ], as in [78–82].
This model shares some similarities with the recent model of Tomasetti and Levy [47], but instead of
modelling an intrinsic drug resistance in chemotherapy, we focus on the dynamics of the drug effects
after the treatment has begun. We are mainly concerned with minimising the escape of the malignant
tumours once the drug is introduced. In addition, in contrast with Tomasetti and Levy [47], we allow
for logistic growth of the tumour cell population. Tumour growth, in reality, is limited by the carrying
capacity of the host tissue, as well as the availability of oxygen and nutrients necessary for its growth.
Models of this type have been found to be appropriate for modelling tumour growth [95, 96]. Fur-
thermore, our mathematical model is in line with many other mathematical models that describe the
dynamics of the drug based on the decay of the external influx of the drug [24,78–82]. To be specific,
here we are primarily concerned with the effects of the drugs on the tumour sensitive cells, while also
taking into account the evolution of a resistant cell sub-population as the treatment progresses.
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2.2.2 Non-dimensionalisation of model equations
In order to facilitate the numerical simulation of the system, we need to non-dimensionalize the
systems. The rationale behind this process is to determine which parameter variations have a more
significant effect on the system and, possibly, to reduce the number of parameters. We take the drug
concentration, D, as a non-dimensional variable, as in [29]. We denote by S? the non-dimensionalised
version of the state variable S and then choose the size of the cell population scale as S0, where S0
is an initial number of sensitive cells. Note, here we have assumed that the eternal drug influx, V ,
is constant for the duration of a chemotherapeutic treatment. Thus the non-dimensionalised state
variables for respective tumour sub-populations and drug concentration using equations (2.4)− (2.6)
are
S = S?S̄, D = D?D̄, D̄ =
1
k
, R = R?R̄, t = t?t̄, t0 =
1
λD
, R0 = θ, (2.8)
and the corresponding model parameters are
V ? = αV, α =
t0
D̄




η = kSt0, a2 = λRt0, µ2 =
S0t0µ
θ
, S̄ = S0, R̄ = R0. (2.10)
Writing the system (2.4)− (2.6) in these new dimensionless variables and parameters, and dropping
the stars for notational convenience, we have
dD(t)
dt








− η(1− e−D)S − µ1S, (2.12)
dR(t)
dt
= a2R (1−R) + µ2S, (2.13)
and corresponding initial conditions are
D(0) = 0, S(0) = 1, R(0) = 1, (2.14)
where the number of initial sensitive cells are given by S0 > 0 and the number of resistant cells are
given by R0 ≥ 0.
2.3 Boundedness, positive invariance and dissipativity
In this section, we establish some important properties of the system (2.11)−(2.13), which ensure that
we have non-negative solutions. The same assurance will be needed for other equations (2.59)−(2.63)
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later in the chapter.
2.3.1 Positive Invariance
All solutions with positive values shall always remain positive. From equation (2.12), one solution
is S ≡ 0; therefore, we observe that no solution S(t) with t > 0 can be zero in finite time, hence
all solutions are non-negative. Similarly, it can be shown that the same analysis leads to positive
solutions of equation (2.13). Finally, from equation (2.11), we note that
dD(t)
dt
= V −D, D0 = 0, (2.15)
where D0 is the initial drug concentration at the time t = 0 and V is a constant external drug influx;
hence there is no solution of equation (2.11) with D(t) > 0 that can be zero.
2.3.2 Dissipativity
A dissipative system is a system whose solutions starting from a certain region, say B, in Rn either
approach, enter or remain in B. For the system (2.11)−(2.13), dissipativity imply that all trajectories
evolve to an attracting region in R3+. However, one should note that the non-negative initial conditions
of the system, does not guarantee that all the solutions shall also be non-negative. From equation























) ≤ a1dt. (2.17)




where A is a constant. Taking the limits on both sides, we have that
lim
t→∞






Now, considering equation (2.13), let R0 ≥ 0 and S(t) = θ1, then
dR(t)
dt














4µ2a2θ1 + (a2θ1)2, (2.21)
and C,A are constants. Taking the limits on both sides of equation (2.20) we obtain
lim
t→∞
sup R(t) ≤ 1
2C
(a2θ1 + ρ) . (2.22)
Similarly, from equation (2.11), we have
dD(t)
dt
≤ V −D, (2.23)
lim
t→∞
sup D(t) ≤ V. (2.24)




∣∣0 ≤ S ≤ θ1, 0 ≤ R ≤ 1
2C
(a2θ1 + ρ) , 0 ≤ D ≤ V
}
(2.25)
as the attracting invariant region of the system.
2.3.3 Boundedness
All the solutions of the system (2.11)− (2.13), with positive initial values are bounded in the region
in R3+ and are attracted to the region B. It is important to note that because we are modelling a
biological system, we can never have negative tumour sub-populations.
2.4 Equilibria and stability analysis: single drug resistance
Determining the solutions of a non-linear system may not be a trivial task. However, through
stability analysis, one can determine the long term behaviour of the system without having to indulge
in a tedious search for solutions. For the models, equations (2.11) − (2.13) and (2.59) − (2.63),
stability analysis is most significant because a stable solution may imply a full remission of the
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tumour sub-populations or at least a condition at which the tumour sub-populations may remain
controllable. Conversely, unstable steady states may imply the relapse of the tumour sub-populations,
corresponding to unsuccessful chemotherapy.
It is of particular interest in this study to determine the asymptotic local stability of the systems.
To achieve this, we linearise equations (2.11)− (2.13) about each of the steady states and determine
the stability of the system.
2.4.1 Drug free equilibrium: single drug resistance
We first investigate the equilibria of equations (2.11) − (2.13) when there is no drug (D(t) = 0 for
all time t). This helps to shed light on how the two tumour sub-populations grow if there is no drug
in the patient’s body. The steady states of the system is found by making the respective derivatives






− µ1S = 0, (2.26)
a2R (1−R) + µ2S = 0, (2.27)
Solving equation (2.26), we obtain the following:




Substituting S = 0 into equation (2.27), we find that
R = 0 or R = 1. (2.29)
If we substitute S = θ1(a1−µ1)
a1
into equation (2.27), we observe that
a2a1R
2 − a2a1R− µ2θ1(a1 − µ1) = 0, (2.30)















Because we are modelling a biological system, we are only interested in steady states which are
positive and real; thus we can only take a positive value for R provided that the discriminant is
non-negative. That is,
µ1 < a1. (2.32)
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Denoting the equilibrium point by Ei = (S
?, R?) , i = 0, 1, 2, and using equations (2.28), (2.29) and
a positive value for R in equation (2.31), we obtain the following steady states:
E0 = (0, 0) , (2.33)
E1 = (0, 1) , (2.34)
E2 =
(
















E2 exists if and only if µ1 < a1. Note, if µ1 = a1, then E2 reduces to E1. This generally means that
equilibrium point E2 exists if the intrinsic growth rate of sensitive population is higher or equal to
the mutation rate of cancerous cells. This is intuitive valid because if the mutations do not occur
at a faster rate than growth of sensitive sub-population, then it might be plausible to inhibit the
occurrence of resistant sub-population. The Jacobian of the linearised system with no drug is given
by
J =
 a1 (1− 2Sθ1 )− µ1 0
µ2 a2(1− 2R)
 . (2.36)
We first evaluate the Jacobian matrix (2.36) about the trivial equilibrium point E0. This reduces to
the matrix
J(E0) =
 a1 − µ1 0
µ2 a2
 . (2.37)
The corresponding characteristic polynomial is given by
γ2 + (µ1 − a2 − a1) γ + a2a1 − a2µ2 = 0. (2.38)
Now, using Routh-Hurwtiz conditions for stability [62], the eigenvalue γ2 = a2 > 0, then no matter
the sign of the eigenvalue γ1 = a1 − µ1 can be, (i.e. either a1 − µ1 < 0 or a1 − µ1 > 0 ) we shall
always have an unstable steady state.
2.4.2 Existence of a globally asymptotically stable point for a drug free
case
Since equations (2.11) − (2.13), are dissipative, as shown in Section 2.3.2, then it suffices to only
prove that there are no periodic orbits associated with the system.
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If there exists a periodic orbit in the system, then using Corollary 1.3.4 of the Poincaré-Bendixson
Theorem, we note that it should enclose the steady state, E0 in this case. Note that if a periodic
orbit existed, then part of the orbit must lie in the dissipative region B in equation (2.25), hence the
orbit cannot be periodic, but rather approach the steady state E0. Therefore, E0 must be a globally
asymptotically stable steady state.
However, we have already shown above that the steady state E0 is unstable; hence there exists at
least one other steady state that is globally asymptotically stable. This can be established from
realisation that when there is no drug infused, equations (2.11)− (2.13) reduce to a two dimensional
system. Thus we can state the following result:
Theorem 2.4.1. If the equilibrium solutions Ei, i = 1, 2 exist, then at least one of the equilibrium
solutions is globally asymptotically stable in R2 \ E0.
Proof. Since we have already established that the steady state, E0 is unstable, and the system is
dissipative, then it suffices to show that there are no periodic solutions. To prove this, we shall utilise
the Dulac’s theorem by choosing B(S,R) = 1
S·R . Applying this to equations (2.11) − (2.13), with



































































This is always true for any two dimensional system, (S,R) ∈ R2+. Therefore, by Dulac’s criterion the
reduced system does not have periodic solutions.
We study the stability of the system about the non-trivial steady state in order to gain an under-
standing of the long term behaviour of the system. The steady state, E1 = (0, 1), represents the
case where the tumour grows to its carrying capacity. This is the most undesirable state because
this state could suggest that chemotherapy is unlikely to be successful. The Jacobian matrix (2.36)
corresponding to the second steady state, E1 = (0, 1), is
J(E1) =




We note that the steady state E1 is locally asymptotically stable only if a1 < µ1 because we have
γ2 = −a2 < 0. The condition a1 < µ1 is plausible in cancer treatment [5] because here it indicates
that the impact of random mutations acquisition on drug resistance is time dependent. In this case
more resistant cells are continuously produced despite the lack of growth of sensitive cells [5]. The
steady state E1 can be the unstable saddle point if µ1 < a1.
The Jacobian matrix (2.36) at the steady state, E2, is
J(E2) =









The equilibrium point E2 would to be locally asymptotically stable only if
µ1 < a1. (2.41)
Otherwise, E2, would be an unstable.
Therefore, we have the following cases for E0, E1 and E2:
(i) If a1 < µ1, then E0 is unstable, but E1 is stable and E2 does not exist.
(ii) If a1 > µ1, then E0 and E1 are unstable, but E2 is stable.
Using parameters from the literature, a1 = 0.18 from [97], a2 = 0.16 and θ = 1.2 × 106 from [98],
µ = 3.67 × 10−6 from [74], and plotting the phase portraits of the system corresponding to E0, E1
and E2, we obtain Figure 2.1.
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Figure 2.1: The phase portraits corresponding to the equilibrium points when µ1 < a1.
In Figure 2.1, the points, E0, E1 and E2, denote the equilibrium points of the system, and the arrows
indicate the direction of the trajectories away from or towards the equilibrium points.
It is important to note that, in the absence of the drug, the system reduces to a two-dimensional
autonomous system. We have used a phase plane analysis to capture the significant features of the
system. The steady state E2 is globally asymptotically stable as shown in Figure 2.1. This confirms
the existence of a global steady state as discussed earlier in this section.
When mutation rate is higher than the intrinsic growth of sensitive sub-population, we have the
following phase portrait:
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Figure 2.2: The phase portraits corresponding to the equilibrium points when a1 < µ1.
From Figure 2.2, we note that the steady state E1 is stable, but not asymptotically. In this case,
we only have two equilibrium points, E0, which is unstable, and E1, which is stable. Intuitively, this
means that if the treatment is taken, then tumour sub-populations would still be driven to extinction,
but not exponentially like in the case when µ1 < a1 as indicated in Figure 2.1.
2.4.3 Treatment equilibrium: single drug resistance
Having shown the dynamical behaviour of the model when there is no drug in at the tumour site, we
next consider the classification of the equilibrium points in the presence of a therapeutic drug. The
equilibrium points, denoted by T (Ei) = (S
∗, R∗, D∗), i = 0, 1, 2 are found by solving the non-linear
system (2.11)−(2.13), with the left sides equated to zero. As before in Section 2.4, the stability of the
system should be found in the same manner. However, the model now involves exponential terms,
which pose a challenge in terms of solving the system algebraically, hence we used the computer
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package SAGE [99] to find the steady states. We found the following plausible steady states:
T (E0) = (0, 0, V ) , (2.42)
T (E1) = (0, 1, V ) , (2.43)
T (E2) = (S


































If condition (2.45) is satisfied, then S∗ and R∗ are positive. This is another necessary condition for
existence of positive solutions in this model. We require position solutions because we are dealing
with biological populations; hence we cannot have negative populations.









0 µ2 a2(1− 2R∗)
 . (2.46)








Here, we observe that the eigenvalue γ1 = −1 < 0, but the eigenvalue γ3 = a2 > 0, hence the steady
state, T (E0), is an unstable saddle point.
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Since the first eigenvalue γ1 = −1 < 0, and the third eigenvalue γ3 = −a2 < 0, then the steady state
T (E1) is stable, but not asymptotically.




























, M23 = 0,








(a1 − (µ1 + η (1− e−V ))).
Since e−V ≤ 1 and given that the condition (2.45) is satisfied, then the eigenvalue γ2 = M22 is






Since γ1 = −1 < 0, then the steady state T (E2) would be locally asymptotically stable.
2.5 The two drug case
One of the major questions in this dissertation is to determine how cancer cells elude the chemothera-
peutic drugs. In such a biologically complex situation, the mathematical model is similarly complex.
Apart from the tumour’s heterogeneity, there are many factors which might substantially alter the
tumour’s responsiveness to the chemotherapeutic drugs. The investigation of these factors has been a
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central focus of both clinical and mathematical oncologists in the last decades [2,45,46,100,101]. The
prevalence of these adverse factors usually leads to the development multi-drug resistance (MDR).
Figure 2.3: The schematic view of the mechanisms that contribute to the development of the multi-
drug resistance (MDR), Source: [2].
Figure 2.3 gives a summary of the factors involved in the evolution of MDR. In many studies,
MDR has been described as the most likely route by which the malignant tumour cells elude the
chemotherapeutic drugs [2, 11, 42, 45–47, 54, 100, 101]. Since some cancer cells may by resistant to
one drug, but be vulnerable to other drug, it is important to consider the evolution of a multi-
drug resistance phenomenon in mathematical modelling. The combination of drugs used in clinical
studies usually includes both cytostatic and cytotoxic drugs. Cytostatic drugs, assist in slowing
down the rapid proliferation of the tumour cells, possibly by inhibiting their growth [55] or by
inhibiting in the growth of the tumour host tissue, and some specific cell functions that are involved
in tumour invasion [102,103]. For instance, Tamoxifen is a drug that is utilised to treat breast cancer
by binding to estrogen receptors on the tumour cells and so inhibiting transcription of estrogen-
responsive genes [104]. In lower dosages, cytostatic drugs are not considered harmful to the normal
cells [45, 47,56,105].
Cytotoxic drugs, on the other hand, can destroy the tumour cells. However, they present problems of
not only the inevitable evolution of multi-drug resistance, but their toxicity to normal tissues [106].
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Furthermore, during chemotherapy, cytotoxic drug kills sensitive cells [8,44,45,47], but the resistant
cells may actually increase; consequently leading to a failure of the therapy. Therefore both drug
types may be used together. Accordingly, in modelling the effects of acquired drug resistance we aim
to minimize the number of resistant cells through studying the effect of two drugs on the tumour
sensitive cells. At present this study is limited to the effect of two drugs, although extension of this
model to account for three or more drugs is possible.
We denote by R1(t) and R2(t) the populations of tumour cells that are resistant to the first and
second drugs, respectively, at time t after the start of the treatment. We further denote with R12(t)
the tumour cells that are resistant to both the first and second drugs. We have also assumed that
the non-cross resistant sub-populations mutate into cross resistant sub-population. We assume that
the drugs are combined (e.g Lapatinib is a combination of two drugs [107]) and hence are infused
simultaneously as a combination into the targeted tumour site. With these notations, we can now
write the model as
dD(t)
dt









































S + µR1(t) + µR2(t). (2.55)
The initial conditions of the system (2.51)− (2.55) are given as
D(0) = 0, S(0) = S0, R1(0) = R01, R2(0) = R02, R12(0) = R012, (2.56)
where each of the initial values is non-negative. Again, we emphasise that the chemotherapeutic
drug, D, represents the combination of two chemotherapeutic drugs, for instance, a combination
of cytotoxic and cytostatic drugs [15, 16, 47, 55, 56, 102, 105–110] or a cytotoxic drug with an ABC-
transport inhibitor [111]. This model setting provides valuable information because if a particular
tumour cell is resistant to one drug, then it may be still vulnerable to the other drug and D remains
the same as in Tomasetti and Levy [47].
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2.5.1 Non-dimensionalisation
As we did in Section 2.2.2 for the simpler model, we again now create dimensionless variables. We
denote by S? the non-dimensionalised state variable S for sensitive cells and choose the order of
magnitude of the cell population scale to be S0. The dimensionless state variables for a two drug-
resistance model, equations (2.51)− (2.55), are
S = S?S̄, D = D?D̄, D̄ =
1
k
, R1 = θR
?
1, R2 = θR
?
2, R12 = θR
?
12,
t = t?t̄, t0 =
1
λD
, S̄ = S0 (2.57)
The additional dimensionless parameters to baseline parameters (2.9)− (2.10) are
V ? = αV, α =
t0
D̄
, µ1 = µ3 = µ5 = µt0, a1 = λSt0, θ1 =
S0
θ




, η1 = kR1t0, aR2 = λR2t0, µ4 =
µt0S0
3R02




















Dropping the asterisks for notational convenience, we write equations (2.51)− (2.55), in terms of the
dimensionless state variables (2.57) as follows:
dD(t)
dt








− η(1− e−D)S − µ1S, (2.60)
dR1(t)
dt
= aR1R1 (1−R1) + µ2S − η1(1− e−D)R1 − µ3R1, (2.61)
dR2(t)
dt
= aR2R2 (1−R2) + µ4S − η2(1− e−D)R2 − µ5R2, (2.62)
dR12(t)
dt
= aR12R12 (1−R12) + µ6S + µ7R1(t) + µ8R2(t), (2.63)
The initial conditions of the dimensionless system (2.59)− (2.63) are given as
D(0) = 0, S(0) = 1, R1(0) = R01, R2(0) = R02, R12(0) = R012, (2.64)
where each of the initial values is non-negative. We shall solve equations (2.11)− (2.13) and (2.59)−
(2.63), using the Matlab numerical solver, ode45, to determine the effects of the chemotherapeutic
drug on tumour reduction.
32
2.6 Equilibria and stability analysis: multi-drug resistance
In this section, we determine all biologically feasible equilibria admitted by system (2.59)−(2.63) and
study the dynamics around each equilibrium point. We first determine the steady states when there
is no chemotherapeutic drug in the tumour. Second, we find all equilibrium points of the system
when there is a dose of the combination drug in the tumour.
2.6.1 Drug free equilibrium: multi-drug resistance
Let the steady states be Ei = (S,R1, R2, R12). Then in order to better understand the dynamical






− µ1S = 0, (2.65)
aR1R1 (1−R1) + µ2S − µ3R1 = 0, (2.66)
aR2R2 (1−R2) + µ4S − µ5R2 = 0, (2.67)
aR12R12 (1−R12) + µ6S + µ7R1(t) + µ8R2(t) = 0, (2.68)
and solve for the state variables. From equation (2.65) we find that




Thus we have two cases:
(i) S = 0,
(ii) S = θ1(a1−µ1)
a1
.
Now, we have the following analysis:
(i) If S = 0, from equation (2.66) we find that




and from equation (2.67), we have that





When S = R1 = R2 = 0, from equation (2.68), we note that
R12 = 0, and R12 = 1, (2.72)
and with S = R1 = 0 and R2 =
aR2−µ5
aR2











(aR2 − µ5). (2.73)
Since we are modelling a biological system, we take the positive R12 provided that µ5 < aR2 .
Similarly, when R1 =
aR1−µ3
aR1











(aR1 − µ3), (2.74)

















(aR1 − µ3) +
µ8
aR2a12
(aR2 − µ5). (2.75)
We only take a positive value for R12 provided that µ3 < aR1 and µ5 < aR2 .
Thus, for the case S = 0, we obtained the following five biologically meaningful steady states:
E?0 = (0, 0, 0, 0) , (2.76)
E?1 = (0, 0, 0, 1) , (2.77)





E?3 = (0, R
???
1 , 0, R
???
12 ) , (2.79)
E4?4 =
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The Jacobian of the system, for i = 0, 1, 2, 3, 4, is given by
J(E?i ) =

a1 − 2a1Sθ1 − µ1 0 0 0
µ2 aR1(1− 2R1)− µ3 0 0
µ4 0 aR2(1− 2R2)− µ5 0
µ6 µ7 µ8 aR12(1− 2R12)
 .
(2.81)
Evaluating the Jacobian matrix about the trivial steady state, E?0 , we have that
J(E?0) =

a1 − µ1 0 0 0
µ2 aR1 − µ3 0 0
µ4 0 aR2 − µ5 0
µ6 µ7 µ8 aR12
 . (2.82)
We observe that the trivial steady state is unstable because the eigenvalue γ4 = aR12 > 0. The
other eigenvalues γ1 = a1−µ1, γ2 = aR1 −µ3, γ3 = aR2 −µ5 can either be negative or positive.
Thus, in any case, E?0 would still be unstable.
The Jacobian matrix corresponding to the second steady state, E?1 , is
J(E?1) =

a1 − µ1 0 0 0
µ2 aR1 − µ3 0 0
µ4 0 aR2 − µ5 0
µ6 µ7 µ8 −aR12
 . (2.83)
Here we realise that because the fourth eigenvalue γ4 = −aR12 < 0, then the steady state E?1
is locally asymptotically stable if and only if a1 < µ1, aR1 < µ3, and aR2 < µ5, otherwise, it
remains unstable.
The Jacobian matrix about the steady state, E?2 , is given by
J(E?2) =

a1 − µ1 0 0 0
µ2 aR1 − µ3 0 0
µ4 0 M33 0
µ6 µ7 µ8 M44
 , (2.84)
where







(aR2 − µ5) (2.85)
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The eigenvalues γ4 = M44 < 0 only if µ5 < aR2 . The eigenvalue γ3 = −(aR2 − µ5) < 0 provided
µ5 < aR2 , hence the steady state E
?
2 is locally asymptotically stable only if the eigenvalues
γ2 = aR1 − µ3 < 0 if and only if aR1 < µ3 and γ1 = aS − µ1 < 0 only if a1 < µ1, otherwise it is
unstable.
The Jacobian resulting from the steady state, E?3 , is
J(E?3) =

a1 − µ1 0 0 0
µ2 M22 0 0
µ4 0 −(aR2 − µ5) 0
µ6 µ7 µ8 M44
 , (2.86)
where







(aR1 − µ3) (2.87)
We note that γ4 = M44 < 0 only if µ5 < aR2 . The eigenvalue γ3 = M22 < 0 only if µ5 < aR2 . The
steady state E?3 would be locally asymptotically stable only if the eigenvalues γ3 = aR2−µ5 < 0
if and only if aR2 < µ5, γ1 = a1 − µ1 < 0 only if a1 < µ1, γ4 = M44 < 0 and γ3 = M22 < 0;
otherwise it would be unstable.
Evaluating the Jacobian matrix about the steady state E?4 , we have the following:
J(E?4) =

a1 − µ1 0 0 0
µ2 M22 0 0
µ4 0 −M33 0
µ6 µ7 µ8 M44
 , (2.88)
where








(aR1 − µ3) +
µ8
aR2a12
(aR2 − µ5) (2.90)
Here, given that µ3 < aR1 and µ5 < aR2 , then the eigenvalues γ2 = M22 < 0, γ3 = M33 < 0 and
γ4 = M44 < 0. Hence, the steady state E
?
4 would be asymptotically locally stable if a1 < µ1;
otherwise it would be unstable point.
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(ii) When S# = θ1(a1−µ1)
a1








(aR1 − µ3)2 +
µ2θ1
a1aR1








(aR2 − µ5)2 +
µ4θ1
a1aR2




















S# > 0, R#1 > 0, R
#
2 > 0, whenever µ1 < a1, µ3 < a2, µ5 < a2. (2.94)
For this case, S# = θ1(a1−µ1)
a1
, we obtained the following steady state:
EP? =
(







The Jacobian matrix of this steady state, EP?, is
J(EP?) =

M11 0 0 0
µ2 M22 0 0
µ4 0 −M33 0
µ6 µ7 µ8 M44
 , (2.96)
where
M11 = −(a1 − µ1), M22 = −
(





































where S#, R#1 and R
#
2 are given in (2.91− 2.93) and satisfy condition (2.94). We realise that if
condition (2.91− 2.93) is satisfied, then all the eigenvalues, γ1 = M11, γ2 = M22, γ3 = M33 and
γ4 = M44 are negative. Thus, the steady state, E
P?, is locally asymptotically stable. Otherwise,
it would be unstable.
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In this section, we have investigated the dynamics of the tumour growth when there in no treatment
given. It is important to note that the existence of stable steady states indicates the plausible points
when cancerous cells my not be harmful to a patient. It is also important to note that some tumours
may remain undetectable for years, while others may grow and metastasize rapidly, and cause death
with a short period [38].
2.6.2 Treatment equilibrium: multi-drug resistance
Determining the steady states of the system (2.59− 2.63) is quite tedious; however, we obtained the
following the steady states denoted by T (Eqii ) = (D




12), for i = 0, . . . , 5:
T (Eq00 ) = (V, 0, 0, 0, 0) , (2.97)
T (Eq11 ) = (V, 0, 0, 0, 1) , (2.98)
T (Eq22 ) =
(





T (Eq33 ) =
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T (Eq44 ) =
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T (Eq55 ) =
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Since e−V ≤ 1, then the equilibrium points T (Eq22 ), T (E
q3
3 ), T (E
q4
4 ) and T (E
q5

















The Jacobian matrix for the system, for i = 0, 1, 2, 3, 4, 5, is given by
J(T (Eqii )) =

−1 0 0 0 0
−ηe−DS TS 0 0 0
−η1e−DR1 mu2 TR1 0 0
−η2e−DR2 µ4 0 TR2 0

































TR12 = aR12(1− 2R12). (2.115)
and given that conditions are satisfied (2.108− 2.110).
Evaluating the Jacobian matrix (2.111) about the steady state T (Eq00 ), we have
J(T (Eq00 )) =

−1 0 0 0 0
0 a1 − µ1 0 0 0
0 µ2 aR1 − µ3 0 0
0 µ4 0 aR2 − µ5 0
0 µ6 µ7 µ8 aR12

. (2.116)
We observe that the eigenvalue γ1 = −1 < 0, but γ5 = aR12 > 0, hence the steady state T (E
q0
0 ) is an
unstable saddle point.
Evaluating the Jacobian matrix (2.111) about the steady state T (Eq11 ), we obtain
J(T (Eq11 )) =

−1 0 0 0 0
0 a1 − µ1 0 0 0
0 µ2 aR1 − µ3 0 0
0 µ4 0 aR2 − µ5 0
0 µ6 µ7 µ8 −aR12

. (2.117)
This implies that the second eigenvalue, γ2 = a1 − µ1, is negative only if a1 < µ1. In that case,
the mutation rate is higher than the growth of sensitive cells. This indicates the impact of random
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mutations whereby the drug resistance acquisition is time dependent. It means that more resistant
cells would be continuously produced, despite the lack of growth of sensitive cells [5]. The eigenvalue,
γ3 = aR1−µ3 and γ4 = aR2−µ5 would be negative only if aR1 < µ3 and aR2 < µ5, respectively. Because
γ1 = −1 < 0 and γ5 = −aR12 < 0, then the state T (E
q1
1 ) is stable if and only if a1 < µ1, aR1 < µ3
and aR2 < µ5.
The Jacobian matrix corresponding to T (Eq22 ) is given as
J(T (Eq22 )) =

−1 0 0 0 0
0 a1 − µ1 0 0 0
−η1e−VR1 µ2 TR1 0 0
0 µ4 0 aR2 − µ5 0





















If condition (2.109) is satisfied, then both eigenvalues, γ3 = TR1 and γ5 are negative. Thus, the
steady state, T (Eq22 ), would be locally asymptotically stable if a1 < µ1 and aR2 < µ5. Otherwise, it
would be an unstable point.
Evaluating the Jacobian matrix, (2.111), about the steady state T (Eq33 ), we have the following
outcome:
J(T (Eq33 )) =

−1 0 0 0 0
0 a1 − µ1 0 0 0
0 µ2 aR2 − µ3 0 0
−η2e−VR2 µ4 0 TR2 0






















Similarly, if condition (2.110) is satisfied,then both the third and fifth eigenvalues, γ3 = TR1 and γ5,
are negative. Hence, the steady state, T (Eq33 ), would be locally asymptotically stable only if a1 < µ1
and aR1 < µ3. Otherwise, it would be unstable.
The Jacobian matrix corresponding to T (Eq44 ) is given by
J(T (Eq44 )) =

−1 0 0 0 0
0 a1 − µ1 0 0 0
−η1e−VR1 µ2 TR1 0 0
−η2e−VR2 µ4 0 TR2 0





































Now, if conditions (2.109 − 2.110) are satisfied, then the eigenvalues, γ3 = TR1, γ4 = TR2 and
γ5 = TR12, are all negative. Therefore, the steady state, T (E
q4
4 ), is locally asymptotically stable only
if a1 < µ1 because the first eigenvalue, γ1 = −1, is negative.
Finally, the Jacobian matrix corresponding to the endemic equilibrium point, T (Eq55 ), is given as
J(T (Eq55 )) =

−1 0 0 0 0
−ηe−V S TS 0 0 0
−η1e−VR1 µ2 TR1 0 0
−η2e−VR2 µ4 0 TR2 0















































If conditions (2.108 − 2.110) are satisfied, then the endemic equilibrium point, T (Eq55 ), is locally
asymptotically stable. Otherwise, it would be unstable. This equilibrium point denotes the point
that could bring cancer cell sub-populations to extinction when the chemotherapeutic drug is induced
into the tumour.
2.7 Summary
In this chapter, two mathematical models describing local interaction of malignant tumour and anti-
cancer agents have been presented. These models are based on compartmentalisation of tumour cells
into drug sensitive and drug resistant sub-populations. The first model developed in this chapter
describes the dynamics of tumour cells’ interaction with a single chemotherapeutic drug. In the second
model, we incorporated the dynamics of a multi-drug resistant phenotype. Equilibrium points of the
model equations and their stability analysis were investigated, and show that the model is stable
under certain conditions. However, because those conditions depend upon the parameter values, the
stable conditionality of model does not always hold. Such stability analysis of the equilibria is an
important aspect of mathematical modelling because a stable point could represent the state where
tumour eradication is feasible, and this point, could then be a target point for chemotherapy. In
this way we have increased our qualitative understanding of the model dynamics in relation to its
stability. In Chapter 3, the model with single drug resistance will be extended to include the spatial
interactions of tumour cells with a chemotherapeutic drug. In Chapter 4, numerical techniques will
be applied to obtain quantitative results for both single and multi-drug resistance cases.
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Chapter 3
A PDE model for drug resistance
3.1 Introduction
Even though ODE models can capture many vital biological processes, some processes can only be
adequately addressed through partial differential equation (PDE) models. Such processes include the
changes in age of the cells (i.e., the time elapsed since mitosis occurred), volume or density of the cells,
their degrees of resistance to treatment, their DNA content or the size of the induced metastases.
Analysis based on spatial and temporal processes takes into account the interactions between the
tumour cells and their environment.
In this chapter, the goal is to develop a deterministic PDE model that describes tumour reduction
by introducing chemotherapeutic drug, while simultaneously attempting to minimise the evolution of
drug resistant phenotype. Our convection-reaction-diffusion model takes into account three important
processes. To be specific, firstly, in order to account for the spatial dynamics of tumour cells, we
have considered a spatial transport equation (based on convection) that governs the concentrations
of tumour cells in response to the chemotherapeutic drug, for a given fixed period of the treatment.
The model also incorporates the local chemical reactions that indicate the tumour’s response to the
chemotherapeutic drug while distinguishing between the drug sensitive and drug resistant tumour
sub-populations. Finally, diffusion is the most significant mode of transport in the interstitial space
around the tumour. Being the dominant transport process once the drug leaves the blood vessels it
accounts for the intra-cellular spread of substances such as drug molecules.
In this way, the model describes the tumour’s response to the chemotherapeutic drug by taking into
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account the fact that chemotherapy is a localised treatment. That is to say, the drug is delivered from
the patient’s vasculature into the tumour by means of blood vessels, which are often dense around
the tumour surface, as shown below
Figure 3.1: The blood vessels that vascularise the tumour, Source: [3].
It can be seen in Figure 3.1 that the tumour is surrounded by blood vessels to transport oxygen and
minerals, which are essential for maintaining tumour growth and allowing for metastasis.
In our model, as in Jackson and Byrne [48], the tumour is viewed as a radially symmetric packed
sphere, of radius R(t), consisting of two types of sub-populations; the drug sensitive and drug resistant
cells. There is an evidence that tumours grown in vitro (see Appendix) have a nearly spherical shape,
but tumours grown in vivo are not [48, 112]. It is thus a moving boundary model, as illustrated in
Figure 3.2(b).
(a) 3D spherical tumour (b) 2D projection
Figure 3.2: The schematic view of a spherically symmetric tumour. The spatial domain is a moving
boundary [0, R(t)] with a radius r = R(t).
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Figure 3.2(a) show a schematic view of a spherical tumour in 3 dimensional space, while Figure 3.2(b)
shows its projection of 2 dimensional setting in order to show a corresponding moving radius.
The geometry of this moving boundary problem, where cell movement is associated only with local
volume changes that accompany cell proliferation and death, has been considered in various studies
such as in [48,113–115]. However, there are models that associate the moving boundary of the tumour
not only with concentration gradients of the chemicals inside the tumour, but also with interstitial
pressure [113]. Because we are mainly interested in the tumour’s response to the chemotherapeutic
agent, in this model we have not considered the impact of interstitial pressure.
We have developed a new model similar to the model of Jackson and Byrne [48], as well as Jack-
son [113], where the chemotherapeutic drug kills all types of tumour cells, subject to different sus-
ceptibilities, by assuming that the drug kills only sensitive cells, and does not have any impact on
the resistant cells. This is a reasonable assumption because the model developed in this study is non
cell-cycle specific. In cell cycle-specific models, chemotherapeutic drugs kill cancerous cells only in
specific phases of the cell cycle [116]. The problem with cell cycle-specific chemotherapies is that
drugs target cells only in certain phases of the cell cycle, and consequently spare some tumour cells
that are not in the targeted phases [117]. We have further assumed that the resistant sub-population
in the tumour is due to genetic point mutations, as in Tomasetti and Levy [47]. Since we are mod-
elling a malignant tumour, we have also assumed the tumour to possess its own vasculature so that
it can receive nourishment sufficient to maintain its growth and malignancy, through both diffusion
and blood-tissue transfer [48,114].
3.2 PDE model formulation
There are many important biological processes involved in the distribution of drugs into the targeted
cancerous cells, as shown in Figure 3.3.
The physical processes involved in the movement of drugs into or out of the tumour cells. Normally,
drug molecules could either traverse from the vasculature (blood vessels) by means of advection
(sometimes called convection) or diffuse through the interstitial space around the tumour; they are
usually subject to some natural decay before they could be up-taken by the tumour cells. During
advective movement, drug molecules are carried with a bulk flow of interstitial fluid. This flow
could result from pressure differences within a tumour tissue or from the drainage of fluids into the
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lymphatic circulation system [4].
Figure 3.3: The biological processes involved in the migration of the drug molecules into the tumour
cells, Source [4].
In some cases, drug molecules are boosted (activated) to increase an efficacy of the chemotherapeutic
compounds as well as to increase the time of drug survival within the tumour tissue beyond its half-
life [4]. For mathematical simplicity, in our model we consider diffusion and convection processes.
Diffusion accounts for the random motility of drug molecules due to gradients in their concentration
while convection usually accounts for the motion of the drug due to bulk motion in the carrying
environment [118].
In order to account for the spatial dynamics of tumour cell sub-populations, where the density of any
species depends on time and space, the ODE model is now extended to a system of partial differential
equations (PDEs). We make the following assumptions for the vascular tumour growth model:
(i) The chemotherapeutic drug reaches the tumour cells mainly by constant diffusion from nearby
vasculature. There is little convectional movement of the drug at the tumour site.
(ii) The chemotherapeutic drug diffuses both ways between the tumour vasculature and the tumour-
host tissue at a rate that is proportional to the difference in the drug concentrations in the blood
and tumour.
(iii) The drug sensitive tumour cells are uniformly susceptible to the drug, and the drug does not
have any effects on the resistant cells.
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(iv) The tumour cells grow logistically in the absence of the chemotherapeutic drug [21,48].
(v) A portion of the drug gets inactivated as it interacts with the tumour cells. As in the ODE
model, we assume that the interaction of the drug with the tumour cells follows an exponential
saturation kinetics.
The model is comprised of a system of partial differential equations that describe spatial interaction
of the chemotherapeutic drug with two tumour sub-populations. The first tumour sub-population
comprises cells that are sensitive to the drug, S(r, t), while the second sub-population is made up of
cells that are resistant to the drug, R(r, t). We follow a similar modelling approach to that adopted
by Byrne and Jackson [48] by considering a vascular exchange between blood and the tumour. We
denote by D(r, t) a drug concentration within the tumour, and by Db(t) the drug concentration
within the blood. We consider a constant rate of transfer of the drug from the nearby vasculature
to the tumour as in [114]. Tumour cell movement is described by the local volume changes that
accompany proliferation and death of individual cells. Such movement is usually associated with a
local cell velocity, u(r, t).
The following are the baseline parameters for our spatially symmetric tumour model:
(i) dD denotes the diffusion coefficient of the drug,
(ii) dS represents the growth rate of the sensitive cells,
(iii) dR denotes the growth rate of resistant cells,
(iv) µ represents the mutation rate coefficient resulting from cell division,
(v) λD denotes the chemotherapeutic decay,
(vi) λS represents an intrinsic growth rate of sensitive cells,
(vii) λR denotes an intrinsic growth rate of resistant cells,
(viii) Γ represents the permeability coefficient between the tumour and nearby tissue vasculature,
(ix) uS represents a rate of inactivation of the drug from an interaction of sensitive cells, S(r, t),
and the chemotherapeutic drug, D(r, t),
(x) kS denotes a susceptibility coefficient of the sensitive cells,
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(xi) k denotes a saturation coefficient of the drug,
(xii) θ represents a maximum carrying capacity of the tumour.
Applying the principle of conservation of mass on each tumour sub-population and drug concentra-
tion, then the model is written as follow:
∂D
∂t
+∇ · (uD) = dD∇2D + Γ(Db(t)−D)− λDD − uSISD(S,D), (3.1)
∂S
∂t





− ISD(S,D)− µS, (3.2)
∂R
∂t






This model shares some similarities with that of Jackson and Byrne [48] in that the local concentration
of each tumour sub-population is subject to both diffusion and convection processes. However, in this
model, reduction of drug concentration does not depend only on natural drug decay, as considered by
Jackson and Byrne [48], but also to inactivation of the drug resulting from drug interaction with the
sensitive cells. To account for this interaction between the tumour and the sensitive cells, we have
denoted this interaction by a term I, for instance, ISD(S,D), represents the interaction of the drug
and the sensitive cells. This interaction, in principle, depends only on the local concentrations of the
sensitive tumour cells, S, and the chemotherapeutic drug, D. In addition, we considered an influence
of genetic point mutations, µ, in the acquisition of resistance phenotype of tumour cells. We also
note that all types of tumour sub-populations have distinct intrinsic growth rates, with the sensitive
cells growing faster than the resistant cells. Furthermore, the chemotherapeutic drug decays at some
specific rate and also diffuses into, or out of, the tumour from the bloodstream in the surrounding
tissue.
Unlike to Jackson and Byrne [48], who assumed Michaelis-Menten interaction kinetics between the
tumour cells and the chemotherapeutic drug, instead because chemotherapeutic drugs are effective
during certain phases of the cell division cycle, we take the interaction term between the sensitive
cells and the drug to follow exponential kinetics as
ISD(S,D) = kS(1− e−kD)S. (3.4)
The interaction of the chemotherapeutic drug and sensitive cells is usually given by exponential
saturation kinetics [97]. This interaction of the sensitive cells and the chemotherapeutic drug has
been validated with medical data by Gardner [90].
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To account for the spherical symmetry of the tumour, we define the tumour boundary by
B(r, t) = r −R(t) = 0, (3.5)











































































To find the equation for the local cell velocity, u, we first assume that there are no empty spaces within
the tumour such that the fraction of the spheroid occupied by the tumour cells remains constant,
and that the proportion of the vascular space within the tumour also remains constant. Under these
assumptions, we can write the following relation for the two tumour sub-populations
S +R = c ≡ constant. (3.9)


























































− kS(1− e−kD)S, (3.10)
where E = (dS − d(c−S)). Equation (3.10) is the equation for the local velocity, u. It suffices to
determine the drug concentration, D, and the radial velocity, u.
To complete our system, we note that the tumour has a moving boundary; hence let r = R(t), then
we impose the following initial conditions:
R(0) = R0, S(r, 0) = S0, R(r, 0) = 0, D(r, 0) = 0, Db(0) = Db0 (3.11)
These conditions imply that the tumour of a given radius R0 comprises only the sensitive cells, S0.
There is no chemotherapeutic drug in the tumour at time t = 0, but there is some chemotherapeutic
drug in the surrounding tumour vasculature.
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To asses the tumour’s response to the chemotherapeutic drug we study the evolution of the tumour’s
volume (V = (4/3)πR3), and note that under radial symmetry, the tumour expands at a rate that
is equal to the radial velocity at the tumour boundary [48]. Hence we have
dR
dt
= u(R(t), t) (3.12)









= 0, u(0, t) = 0. (3.13)
Since the tumour is assumed to be spherical, then at r = 0 there is no influx of the drug and the
local radial velocity is zero. We further propose that there is no flux of tumour cells at the tumour
center. To model the temporal and spatio-temporal equations through the continuity conditions at









= 0, D(r, t) = DN(t). (3.14)
Here, we have denoted the local concentration of the drug at the tumour boundary by DN(t). For
mathematical simplicity, the concentration of the drug in the blood, Db(t), and the amount of the
drug at the tumour boundary, DN(t), are assumed to be constants as in [113]. In [48] they are
regarded as bi-exponential functions.
As in previous chapters, we now define dimensionless variables and parameters where









λ?R, Db = D
?
bD̄, S = S
?S̄, (3.15)









d?R, r = R0r


























































, S̄ = S0. (3.19)
Using these dimensionless variables and parameters, (3.15) − (3.19), in equations (3.6) − (3.8), and
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+ ρRR (1−R) + µ2S (3.22)























+ ρRR (1−R)− η(1− e−D)S. (3.23)
In this section we have now developed a model to describe the spatial dynamics of the tumour
sub-populations and their interaction with the chemotherapeutic drug. This would be helpful in
demonstrating the importance of space for tumour modelling. Furthermore, this would also be
helpful for investigating the partial distribution effects of drugs on tumour growth.
3.3 Analytical solutions of the PDE model
Due to the complexity of the model, we do not expect to obtain the full analytical solutions of
the model. Nevertheless, full solutions will be obtained derived numerically in Chapter 4. In the
meantime, we can obtain analytical solutions for the local drug concentration and the local velocity,
with transformation and additional assumptions. The full solution of the model shall be derived
numerically in Chapter 4.
Firstly, we introduce a small parameter 0 ≤ ε = R20/dD  1 which is a similar transformation as was































Then, following the method of multiple time scales [119, 120], we have adopted two time scales
for our model: the intrinsic tumour growth scale (≈ 1 day), and the shorter diffusion time scale
(R0/dD ≈ 60 seconds) [48]. Assuming that the chemotherapeutic drug diffuses much faster than the


















Note that equation (3.25) is a homogeneous first order partial differential equation; hence we can
find the solution to it.
Next, if we further assume a low chemotherapeutic drug concentration, then 1 − e−kD ≈ kD. This












λD + Γ + uSkSkS
dD
)





λD + Γ + uSkSkS
dD
, (3.27)














Let us define another function D = G(r, t)/r, then we can write




We choose the particular solution to equation (3.29) as Gp =
Γ
dD
Db(t). The corresponding homoge-
neous equation to (3.29) is
G′′ − ξ2DG = 0. (3.30)










− (kj)2fj + γj = 0, (3.31)
which is a mass balance equation and could be solved with appropriate boundary conditions [121–124].
The formulation and solutions of the equations of this type are discussed in detail by Deen [123] and
Bird et al [122].
The general solution to equation (3.28) is
D(r, t) =






where a(t) and b(t) are functions that are determined from the boundary conditions. To find the
solution for the local drug concentration, we demand that the chemotherapeutic drug concentration
approaches a steady state in the blood tissue. This can occur only if a(t) + b(t) = 0. Since we have





= 0, hence b(t) = 0. (3.33)
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Here, we have only provided the analytical solution for the local drug concentration based on the
assumption of induced low drug concentration at the tumour site. This solution is similar to the one
attained by Jackson and Byrne [48]. The solution for high drug concentration can only be found
numerically.
We next find the equation for the local velocity, u(r, t), by substituting equation (3.36) into equation
(3.23). Let us first make the following assumptions;
(i) The intra-tumour drug concentration, D, is low and constant. This implies that 1−e−kD ≈ kD.
It is important to note that at relatively low drug concentrations, this interaction term is nearly
linear, whereas at higher drug concentration, the drug concentration within the tumour reaches
a saturation state (i.e a response curve plateaus). This exponential term corresponds to drug
response kinetics suggested by Gardner [90].
(ii) The tumour consists of only sensitive cells (i.e. one cell type, S(r, t) = 1). Thus, there are no
resistant cells, R(r, t) = 0.








= 1− kSkD. (3.37)




















































Integration by parts, equation (3.39) becomes















































With this solution for the local cell velocity, we can now follow the tumour’s expansion by tracking























These solutions, when one type of tumour cell is present (primarily sensitive cells), is that tumours
would usually regress once a chemotherapeutic drug is infused at the tumour site. When there are two
types of the tumour sub-populations, the dynamics become complex. We shall attempt to capture
some essential aspects of the model numerically in Chapter 4. We remark that the analysis and
solutions provided here are only valid if we have a spherical geometry. These results would differ
for non-spherical tumours and are not applicable where there are drug resistant tumour cells. More
importantly, the establishment of these results is important because, by our model assumption, the
resistant sub-population arise from mutation of a single sensitive cell. Thus, it is essential to track
the dynamics of tumour growth prior to evolution of a drug-resistant sub-population. However, the
model dynamics when there are two types of tumour sub-populations (i.e. the sensitive and resistant
cells), will be investigated numerically in Chapter 4.
3.4 Summary
In this chapter, we enhanced our understanding of the spatial dynamics that underlie a tumour’s
growth with the intervention of a single chemotherapeutic drug. The presented model described the
evolution of tumour sub-populations both in space and time. Our model shares some important
similarity and analysis with that of Jackson and Byrne [48] for one cell type. The model follows the
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evolution of tumour sub-populations in spherical geometry. Since the drug resistant tumour sub-
population results from genetic point mutations of the sensitive cells, we analysed the model when
one type of tumour cell exits. This analysis helped to follow the spatial evolution of the tumour as
described by the radial velocity of the tumour at the boundary, u(R(t), t), shown in equation 3.42.
In the following chapter, we shall provide numerical simulations of the model to better understand
the model dynamics that could lead to fail or success of the treatment for combating tumour cells.
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Chapter 4
Numerical results and discussion
The main goal of a chemotherapy treatment is to reduce the tumour volume to a smallest possible
burden at the end of the therapy. Consequently we have already analysed the two ODE models in
order to gain insight into the dynamical behaviour of models’ response to small perturbations as
illustrated by the stability of the models’ equilibrium points. In this chapter, we now present the
numerical findings for the ODE and PDE models that were developed earlier in Chapters 2 and 3. We
solved the ODE model using Matlab’s built-in solver, ode45. The ode45 uses a Runge-Kutta method,
with a variable time step, to compute a solution of a given differential equation. For the PDE model,
we used Matlab’s built-in solver, pdepe, which converts a PDE to a coupled set of ODEs using a
second-order spatial discretization based on a fixed set of specified nodes. For intuitive analysis of
the models, the dimensionless variables and parameters have now been re-defined in terms of the
similar variables and parameters as in the original models.
4.1 Sensitivity analysis
In order to check for a monotonic dependence of sensitive cells on the baseline parameters, sensitivity
analysis was performed on the ODE systems (2.11) − (2.13), and (2.59) − (2.63). Because we have
assumed that only sensitive cells can mutate into a resistant sub-population, it is important to
investigate the influence of the baseline parameters of the model relationship of on the sub-population
of sensitive cells. If many sensitive cells could be eradicated by the chemotherapeutic drug, then
there would be few or, possibly, no sensitive cells that might subsequently mutate into a resistant
sub-population.
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We provide the outcomes of the partial rank correlation coefficient (PRCC) analysis over 500 ran-
domised parameter values, with respect to sensitive cells, using Latin hypercube sampling [71, 72].
We have regarded the external drug influx, V , as a one of the baseline parameters in order to check
its contribution to the models monotonicity for tumour sensitive sub-population.
To effectively model drug resistance, we needed to deduce which parameters are in the model are
most correlated with the sensitive sub-population. Thus the PRCC results allow us to determine
which of the parameters could be most effectively controlled in order to mitigate cancer occurrence.
Thus PRCC results are used to identify the key parameters that contribute most significantly to
the sensitive cell density. The PRCCs were computed for each of the input baseline parameters
and the state variable S(t), representing the population of sensitive cells. Scatter plots for each
baseline parameter and the number of sensitive cells were generated and examined for any monotonic
dependence of the sensitive cell population on the given parameter.
As explained in Section 1.4, the magnitude of the PRCC illustrates the strength of correlation between
the two quantities, while the sign of the PRCC indicates the qualitative relationship. Typically, a
significant positive PRCC value implies that if values of one variable (i.e. the parameter under study)
increases, then the values on the second parameter (i.e. sensitive sub-population), would also increase
correspondingly, given that other parameters are held constant. Similarly, a significant negative
PRCC tells us that as the input variable increase, then the outcome variable would correspondingly
decrease. The PRCC results for equations (2.11) − (2.13) are given in Table 4.1, and for equations
(2.59)− (2.63) in Table 4.2.
Table 4.1: The PRCCs between the input parameters for single drug resistance phenomenon and the
output variable (sensitive cells).






Parameter PRCC Parameter PRCC
λD −0.94542 λS 0.018136
µ 0.041334 λR 0.060717
kS 0.025807 V 0.9152
k −0.070753 θ −0.031957
It can be seen from Table 4.1 that the external drug influx (V ) and the natural decay of the drug (λD)
both have PRCC, in magnitude, close to 1. Thus we conclude that they contribute most significantly
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to the density of the sensitive sub-population. This further highlights the role of the chemotherapeutic
drug in minimising the survival opportunities of the tumour sensitive cells. Furthermore, we note
that the positive value of PRCC for V indicates that an increase in the chemotherapeutic drug influx
should result in the number of sensitive cells also increasing. Corresponding reasoning can be applied
to the negative value of the PRCC for λD indicating that an increase in the drug decay rate would
lead to a decrease in the number of sensitive cells.
Since we have many parameters in the model, the indices of the PRCC are also crucial in determining
the effect of each individual parameter in metastasis dynamics and prevalence of multi-drug resistance.
So similarly, we computed the PRCC for equations (2.59) − (2.63), and obtained the results in
Table 4.2.
Table 4.2: PRCC results for the multi-drug resistance phenomenon






Parameter PRCC Parameter PRCC
λR12 0.075714 k −0.023531
kR2 −0.025612 kS 0.076146
λR2 0.072677 θ −0.047579
kR1 0.0089081 λS 0.04642
λR1 0.1137 λD −0.94691
µ 0.0.0078702 V 0.91861
As before, Table 4.2 illustrates the degree of influence of each parameter on the sensitive sub-
population, given that all the influences of other parameters and variables could be completely
removed. The results of the PRCC for the model with multi-drug resistance shown in Table 4.2 show
that, again, the external drug influx, V , is a parameter that is highly positively correlated with the
number of sensitive cells, while the drug decay, λD, is highly negatively correlated with the number
of sensitive cells. The positive correlation implies that the number of sensitive cells would increase
depending on the prevalence of the drug at the tumour site. This further suggests that if the number
of sensitive cells increase, then the external drug influx should be increased. However, the increase of
drug influx should be within tolerable toxicity constraints. Determination of an optimal drug influx
shall constitute our future work on this model.
On the other hand, the negative correlation between drug decay and the number of sensitive cells
58
implies that when a drug with low decay rate is used, then the number of sensitive cells decreases. If
the drug does not decay quickly, many sensitive cells would be killed by the drug elimination from a
surrounding tumour tissue can take place due to natural decay [4]. Because chemotherapeutic drug
molecules are subject to natural decay before they are taken up by cells [4], it clear that if the drug
does not decay fast, then many drug molecules would interact with sensitive cells. These results
appear to show that drug decay is an important aspect to consider for chemotherapeutic modelling.
In this regard, Feizabadi et al. [24] argued that success of a chemotherapy regimen may be greatly
influenced by the decay rate of the drug.
4.2 Solution of model with single drug resistance
In this Section, we investigate the dynamical behaviour of the model (2.4)− (2.6). We assumed that
the resistant tumour sub-population is only resistant to one cytotoxic drug. The sensitivity analysis
has shown that the external drug influx V , and the molecular drug decay, λD, are the most influential
parameters in the model. Hence we shall separately investigate the dynamical response of the system
to small variations in each of these two parameters.
We have taken the fixed time period of a chemotherapy simulation as [0, 60] days and assumed the
following initial conditions for the model: S(0) = 1×1012, R(0) = 0, D(0) = 0, as also used by Monro
and Gaffney [11].
For the model simulations, we have used parameters from various literature sources that deal with
the effects of drug resistance, and/or tumour burden reduction. However, there is no consistent
plethora of tumour and chemotherapeutic drug interaction data available to choose from. Thus, for
some parameters, we have estimated the values (parameter fitting) based on similar parameters from
available literature sources. For instance, there is an evidence that resistant cells proliferate slower
than sensitive cells [46]. The baseline parameters are given in Table 4.3.
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Table 4.3: List of baseline parameter values utilised in the simulations of the model with single drug
resistance and their sources.
Parameter Value Source
λD 1.9/day λ [48]
µ 1× 10−6/day µ [83, 125]
kS 0.6/day d1 [83]
k 1.179 mL/nmol σT [29]
λS 4.31× 10−1/day a [20]
λR 4.31× 10−1/day Parameter Fitting
V 5.1/day V [6]
θ 2× 1012 nmol N∞ [11]
4.2.1 Results
We first investigated the tumour growth in the absence of the drug. Two numerical solutions using
parameter values in Tables 4.3 but with different initial values for the sensitive cell population are
presented in Figures 4.1(a) and 4.1(b). Figure 4.1(a) shows the growth of tumour sub-populations
when the initial number of sensitive cells is S(0) = 1×1012, while in Figure 4.1(b) the initial number of
sensitive cells is S(0) = 0.2×1012. In both figures, we note that all graphs reach the same asymptote,
which indicates that the respective tumour sub-populations grow to the maximum carrying capacity
in the host tissue in the absence of the drug. This suggest that once the tumour has been detected,
there is an immediate need for medical treatment. Furthermore, comparing the two figures, it can
be seen that if, at the start of the therapy, there are initially more sensitive cells, Figure 4.1(a) the
tumour cells would quickly grow to the carrying capacity of the host more rapidly. With both graphs,
in both figures, reaching the same asymptote imply that there are now equal number of sensitive and
resistant cells.
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(a) S(0) = 1× 1012. (b) S(0) = 0.2× 1012.
Figure 4.1: The tumour growth when there is no chemotherapeutic drug.
The first step in addressing drug resistance is to kill the drug sensitive cells, so as to give them
no chance of mutating into the resistant sub-population. In this regard, the sensitivity analysis
(Section 4.1) showed that the amount of the chemotherapeutic drug infused into the tumour can
have considerable consequences on the success of the treatment. Thus, we varied the values of V,
representing the cytotoxic drug dose. However, to avoid drug toxicity constraints, we have limited
the values, while yet still maintaining a sufficient amount of the drug to induce lethal outcomes on
the sensitive cells. Consequently, we have adopted the maximum drug dose as V = 5.1, as from [6],




Figure 4.2: The finite continuous chemotherapeutic treatment on the sensitive cells with different
drug doses.
The graphs of S(t) in Figure 4.2(a) − 4.2(c) are all asymptotically decreasing. However, in Fig-
ure 4.2(a) this non-zero asymptote indicates that with a low chemotherapeutic drug dose (V = 1.1),
the number of sensitive cells initially drops but then remains at more than half the initial value.
This contrasts with the higher dosages represented in figures 4.2(b) and 4.2(c). In these, we note
that the drug sensitive population is quickly reduced to an insignificant amount. Similar high dose
strategies has been found to be effective against the more drug sensitive cells of the tumour, such as
in lymphoma, leukemia and germ cell tumour [9]. In all three graphs it can be seen that the drug
resistant cells continued to multiply to a maximum, unaffected by the treatment.
Other insightful results are obtained if we vary the drug decay rate, because if the drug does not
decay too quickly, then for longer periods, there should be a reasonable amount of the drug available
to kill the tumour. With drug dose now fixed at maximum tolerable content, V = 5.1 per day, we




Figure 4.3: Simulations tumour growth subject to different drug decay rate.
Figure 4.3(a)− 4.3(c) show reduction of the sensitive cells with different, reducing, drug decay rates.
In Figure 4.3(a) fewer sensitive cells are killed, and moreover, their number remains as slightly less
than half the initial amount. In Figure 4.3(b), we have a drug with an average decay rate of 4.5 and it
can be seen that the graph does take longer time to reach an asymptotic horizontal value (S(t) = 0),
but this is close to zero. Thus, we conclude that while eradication of sensitive cells takes a longer
period of time, there ultimately remain very few sensitive cells. Mathematically, it is possible to have
a limiting case of no drug decay as shown in Figure 4.3(c). This is presented for comparison, but in
biological situations there is always a natural decay for each drug [24]. Once again it can be seen
that the drug resistant cells were unaffected by the treatment.
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Our results are in accordance with other published findings. In this regard, Feizabadi et al. [24]
obtained results for different decay rates in their model, and argued that success of a chemotherapy
regimen may be greatly influenced by the decay rate of the drug. Similar findings suggest that if
the drug has a lower decay rate, then opportunities for successful treatment are increased, provided
that the drugs effectively penetrate the tumour at lethal concentrations [43,126,127]. Such successful
treatments would not allow the sensitive sub-population to accumulate enough mutations to become
malignant.
4.3 Summary
In this section, we have provided results of the model with a single drug resistance. In particular, we
have identified, through sensitivity analysis (Section 4.1), model parameters that are most influential
to the number of sensitive cells. By varying those parameters, we have observed some significant
reduction in the number of sensitive cells, which, if not eliminated, may contribute to an increase in
the number of the resistant tumour sub-population. However, in all cases, development of resistant
sub-population is inevitable. As highlighted in a recent review [111], the cancerous cells that recur
after a single treatment may be resistant to multiple drugs. It was therefore important to investigate
the dynamics of multi-drug resistance in this model. This is done in Section 4.4 below.
4.4 Solution of the ODE model for a multi-drug resistance
As pointed out in Section 2.5 one of the reasons ascribed to the failure of the chemotherapeutic
treatment is the development of the multi-drug resistance phenomenon. In this section, we provide
the simulated results for the multi-drug resistance with two chemotherapeutic drugs.
Again, as with the single drug case, some model parameters are not available in the literature,
hence, for modelling purposes, we have estimated missing parameters (Parameter fitting) based on
the available information pertaining to their properties. The baseline parameters of the model are
given in Table 4.4,
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Table 4.4: List of baseline parameter values used for simulations using equations (2.51)− (2.55).
Parameter Value Source
λD 1.9/day λ [48]
µ 10−1 − 10−6/day µ [83, 125]
kS 0.6/day d1 [83]
k 1.179 mL/nmol σT [29]
λS 4.31× 10−2/day Modified a from [20]
λR1 3.84× 10−2/day Parameter Fitting
λR2 2.81× 10−2/day Parameter Fitting
λR12 2.5× 10−2/day Parameter Fitting
V 5.1/day V [6]
θ 2× 1012 nmol N∞ [11]
4.4.1 Results
Here, we are intrigued by the following question, “does increasing the number of drugs improve the
opportunities of chemotherapeutic success?”. This question has been addressed in numerous studies,
but there is no unique answer to it. In particular, we note the view of Komarova and Wodarz [54]
who argued that success depends on the mutation rate and the death rate of the tumour cells. They
emphasized that the higher the mutations acquisition, the lesser the effect of incremental increases
in the number of drugs, with more likelihood of the tumour becoming difficult to treat. Using the
baseline parameters given in Table 4.4, our results are shown in Figure 4.4.
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(a) (b)
Figure 4.4: The dynamical behaviour of the tumour sub-populations, subject to high mutation rate
and different drug doses.
Figures 4.4(a), we note that , with low drug dosage, if there are higher mutation variations in the
tumour while the sub-populations represented as S,R1 and R2 do reduce by 40 days, the population
of multi-drug resistant cells represented as R12 continues to increase, similar to the findings in [5,
41, 47, 51, 52, 54, 111, 125, 128]. To determine whether higher dosage would be even more beneficial,
we investigated the effects of continuous infusion of high drug dose to the tumour site. The results
are illustrated in Figures 4.4(b). When comparing Figures 4.4(a) and 4.4(b), we note that with
a higher dose, the populations of sensitive cells are significantly decreased in less than 10 days
while in Figure 4.4(a) takes more than 10 days to decrease to zero. Thus in comparing the results
for low dosage in Figures 4.4(a) with high dosages in Figure 4.4(b), when we have high mutation
rates, it appears that higher drug doses, within toxicity constraints, are more beneficial than lower
drug doses in order to minimise the occurrence of non-cross resistant cells (i.e. cells that are not
multi-drug resistant). Therefore, this partially explains some apparently contradictory findings in
the literature. To be specific, in some studies low continuous drug dose has been identified as the
most effective treatment dosing strategy for chemotherapy [54,129]. On the other hand, some studies,
have suggested that higher concentrated drug doses are more beneficial [42,130]. However, our results
show substantial advantages of high continuous drug dosing strategy in preventing the development
of drug resistance, subject to high mutation rates, and partially inhibiting an increase in resistance
in multidrug-resistant tumour sub-population.
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These results highlight an important prediction by Goldie and Coldman [5] which links the success
of a therapy to the number of cellular mutations. As described in [5], this relation is given by the
following equation:
P (α) = e−α(N−1), where N(t) = S(t) +R(t), (4.1)
and α is the varying mutation rate, and N(t) is the tumour density with drug sensitive, S(t), and
resistant, R(t), sub-populations. As the number of mutations increases, the probability of having
zero resistant sub-population declines. This result is shown in Figure 4.5.
Figure 4.5: The probability of zero resistant cells as mutations increase [5].
Figure 4.5 shows the effect of mutation rate on the probability of attaining zero resistant tumour sub-
population. The probability of zero resistant cells, is implicitly captured by our model as illustrated
in Figure 4.4(a) and Figure 4.4(b), which both show a persistent increment in the cross resistant
sub-population, R12, despite multi-drug treatment.
As with the single drug resistance case, before investigating the effect of a multi-drug regimen, we
establish a comparative baseline of following the evolution of the tumour sub-populations when there
is no treatment given. We use the baseline parameters in Table 4.4 for the simulations. The results
are given in Figure 4.6.
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Figure 4.6: Relative growth of tumour sub-populations in the absence of the treatment, t ∈ [0, 500]
and S(0) = 0.1× 1012.
Figure 4.6, it can be seen that the growth of all tumour sub-populations in the absence of a chemother-
apeutic drug approach the maximum carrying capacity, θ = 2× 1012, and the population of sensitive
cells quickly proliferates up to the maximum carrying capacity of the tumour.
In order to gain insight into the dynamics of multi-drug resistance, we next investigated the effect
of three different chemotherapeutic drug doses on the cell sub-populations. The results are shown in
Figure 4.7(a)− (f)
From the graphs in Figure 4.7 it can be seen that with any dose, the graphs of S,R1 and R2 all follow
similar patterns to S and R in the single drug resistant model. By this we mean that with a low
dosage (a), the population of sensitive cells decreases, but not as quickly a in high dosage, (e). With
higher dosages, S(t) appears to drop to zero between 12 days (c) and 10 days (e). This indicates
that a high infusion of the combination of chemotherapeutic drugs, V , might be a valuable strategy
to eradicate the sensitive sub-population. And under any dosage, R1 and R2, initially increase and
then drop off to zero.
Nevertheless, the multi-drug resistant cells, shown by R12, maintain the tumour’s proliferation, up
to the maximum carrying capacity of the tumour cell, under any dosage, although the higher the
dosage, the less rapidly it increases. For the tumour this means that higher drug doses yield more
efficacious outcomes. With the drug dose within the toxicity constraints, then the majority of both
sensitive and non-cross drug resistant sub-populations are greatly reduced, but the cross resistant





Figure 4.7: The response of the tumour sub-populations to various drug doses in multi-drug resistance
case.
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In all the figures for the resistant sub-populations in Figure 4.7, the curve for the multi-drug resistant
sub-population, as indicated by R12, keeps increasing to the maximum carrying capacity of the
tumour. This highlights the fact that multi-drug resistant sub-population is, generally, not easy to
control. That is why multi-drug resistance has always be ascribed as a major source of failure in
many chemotherapeutic treatments [2].
4.5 Solution of the PDE model without the interstitial con-
vection
In this section we provide the numerical solution of equations (3.20) − (3.22). These equations
represent an interaction of the tumour cells with a single chemotherapeutic drug. The diffusive flux
is a major modal transport by which the chemotherapeutic drug could reach the tumour. Hence,


















































First, in order to gain some insights into the mechanical behaviour of the model, we considered
different initial conditions. The solutions presented in this section were found using a finite difference
based PDE solver in Matlab, pdepe. We solved equations (4.2)− (4.4) with initial conditions (3.11),
and boundary conditions (3.13) and (3.14). For the model simulations, we used the initial conditions
Db(0) = 1.179, S(r, 0) = 4 × 103, R(r, 0) = 0, D(r, 0) = 0 to investigate the effects of the growing
tumour subject to diffusion of the chemotherapeutic drug from the surrounding vasculature.
The parameter values used in the simulations are given in Table 4.5. We obtained some parameter
values from Jackson’s models [48] and other literature relevant sources, as shown in the table. Because
there is no consistent data for any type of cancer [10], we had to use some parameters that relate to
a variety of cancer types. The baseline parameters and the initial conditions are varied in order to
investigate the tumour’s behaviour with respect to different mutations.
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λD 1.9/day λ [48]
µ 1× 10−3/day µ [125]
Γ 16/day Γ [48]
uS 0.021/day Parameter Fitting
kS 42.8/day kT [29]
k 1.179 mL/nmol σT [29]
λS 0.18/day a [97]
λR 0.15/day Parameter Fitting
θ 2× 106/nmol M [131]
4.5.1 Results
We begin by evaluating the model response to different initial numbers of sensitive tumour cells,
because we assumed that the resistant sub-population evolves from the mitosis of the sensitive cells.
This consideration is vital in those instances where the acquired drug resistance might be dependent
on the size of the tumour. In this regard, the initial tumour size plays an important role predicting
the equilibrium state from the start of the therapy [132]. When medical treatment is given to a
cancer patient, the tumour cells could be driven to either no tumour equilibrium or large tumour
equilibrium [132]. The latter state is usually held responsible for failure of many chemotherapies due
to the evolution of drug resistance.
If we have no drug present, and initially only sensitive cells, we then investigate the effect of tumor
size using S(0) = 5× 1011 in Figure 4.8.
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Figure 4.8: The comparison of the tumour sub-populations growth without drug.
As with the ODE model, equations (2.4) − (2.6), Figure 4.8 show that if there is no drug at the
tumour site, and an initial tumour size is large, then the tumour sub-populations would rapidly
proliferate to the maximum carrying capacity of the host tissue. This further indicates that larger
tumours are more difficult to treat by chemotherapy or radiotherapy [133], and usually, the tumour
would grow to a dangerous level if left untreated. However, if the initial numbers of sensitive tumour
cells is small, S(0) = 4× 103, we obtain results in Figure 4.9.
(a) (b)
Figure 4.9: Tumour sub-populations with small initial size, S0 = 4× 103.
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Figure 4.9 gives a comparison of tumour growth for the two sub-populations when the initial number
of sensitive cells is small. As show in Figure 4.9(a), if the initial number of sensitive cells is small, then
the tumour could be eradicated before the evolution of the drug resistant sub-population. This is
shown in Figure 4.9(a) whereby the sensitive cells are eradicated on 10th day, while the evolution of the
resistant tumour sub-population occurs on the 25th day as shown in Figure 4.9(b). From these results
we note that treatment of small tumours may help to circumvent a problem of drug resistance because
sensitive cells could be eradicated before the evolution of the resistant sub-population. However, small
tumours may not be easily identified until they have reached a certain detectable size [20].
It was necessary to further explore a optimal time to eradicate a tumour with small initial number of
sensitive cells at the start of therapy, S0 = 4×103, and we obtained the results shown in Figure 4.10.
Figure 4.10: Simulation of the smallest time for the eradication of a tumour with small number of
sensitive cells.
Figure 4.10 indicates that, under our model assumptions, the tumour’s eradication with a chemother-
apeutic drug is plausibly within 9 days. This further shows that continuous infusion of chemothera-
peutic drug is better strategy to reduce a tumour burden [134].
It is of particular interest to determine the dynamics of the tumour’s response to the chemotherapeutic
drug. To achieve this, we have numerically solved the model with and without the drug and using
S0 = 5× 103, θ = 2× 1012 and µ = 1× 10−6 as recommended in [11]. We obtained the results shown
in Figure 4.11.
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Figure 4.11: The solution of the model with a chemotherapeutic drug.
Figure 4.11 shows the tumour growth profile with interventions by chemotherapeutic drug. Compared
to Figure 4.8, it can be seen that with no drug present there is the inevitable growth in cancer cells.
However in Figure 4.11, as with many cytotoxic drug models, the simulations show that for certain
initial and boundary conditions, eradication of the sensitive cells is possible. However, the evolution
and growth of the resistant sub-population remain inevitable. Although further studies must be
conducted, our results to date indicate that continuous infusion of a chemotherapeutic drug could be
useful to eliminate the drug sensitive cells, while diminishing the opportunities for the development
of drug resistance. This outcome is important for our model because we assumed that the resistant
tumour sub-population arise from genetic mutations of sensitive cells. Thus, the benefits of this
treatment strategy could help to combat drug resistance by giving sensitive cells no chance of quickly
mutating into drug resistant sub-population.
4.6 Summary
Mathematical modelling and computer simulations are tools that provide a robust framework for
better understanding of cancer progression and response to treatment. In this chapter, we solved
numerically both the ODE and PDE models. Through sensitivity analysis of the ODE models, pa-
rameters that contribute most significantly to the tumour’s response to therapy were identified as
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external drug influx and drug decay. Numerical simulations obtained in this study demonstrate the
qualitative effect of various initial conditions and boundary conditions of tumour sub-populations.
Specifically we have shown that for the tumour with high genetic point mutations, high dosage of
a chemotherapeutic drug could be used to eradicated sensitive cells, thereby minimising the devel-
opment of resistant sub-population. For cases where diffusion of anti-cancer drugs into or out of
the tumour is a major mode of transport, continuous infusion of the drug might help to eliminate
drug sensitive sub-population. Because the development of drug resistance is a major impediment
of chemotherapy success, the results presented in this study support the clinical implementation of
a continuous infusion of a chemotherapeutic drug, within toxicity constraints, to prevent the devel-
opment of drug resistance in tumours. The mathematical models developed in this study provide a
significant level of new understanding of these interactions. Nevertheless, the complex interactions
between a tumour and the anti-cancer agents are still poorly understood from biological and math-





In this dissertation, we sought to understand and model local interactions between tumour cells and
anti-cancer agents, while including the evolution of drug resistance. We further sought to enhance
our understanding of the effect of different interventions on the tumour cell sub-populations through
qualitative and numerical analysis. We formulated and analysed two mathematical models that
take into account the effects of drug resistance in cancer. The numerical simulations showed that a
combination of two drugs that are functionally and structurally different may succeed in eliminating
the drug-sensitive and non-cross resistant cells. However, we found that multi drug resistant cells
continued to proliferate.
In Chapter 2, we developed two new ODE models that describe the local interaction of the tumour
cells and anti-cancer agent(s). These models comprise two tumour sub-populations, namely the drug
sensitive cells, S(t), and the resistant cells, R(t). We considered two situations, specifically where
there was resistance to one drug or two drug. The mechanisms underlying multi-drug resistance
are both biologically and mathematically complex, but we were able to determine the stationary
states of these systems and analysed their stability. In both models, non-trivial equilibrium states
were found and the conditions that confer stability were determined. Biologically, these states and
stability conditions indicated that conditions under which the tumour could be harmful or not if
not eradicated from the body. In particular, a stable steady-state solution imply that the tumour
can remain inside a host tissue of a patient for a long time without causing much evasion on the
surrounding tissues [135]. On the other hand, an unstable tumour is likely to metastasise to other
tissues [135]. These findings were different from those already published, in that they do not only give
a qualitative understanding of a tumour progression and metastasis, but they also give a valuable
76
information on the conditions under which the tumour could confer resistance to chemotherapeutic
drug(s). However, under certain conditions, the ODE models have certain limitations because they
do not include the spatial dynamics of tumour cells. Normally, tumour sub-populations compete for
space and resources necessary for their growth and metastasis [55]. We incorporate this feature into
our partial differential equation (PDE) model in Chapter 3.
In Chapter 3, we presented a mathematical model that includes spatial dynamics of the tumour and
chemotherapeutic agents. This is a convection-reaction-diffusion model type with spherical geometry.
We distinguished between the sensitive, S(r, t), and resistant, R(r, t), sub-populations. Analytical
solutions of the chemotherapeutic drug concentration and the local velocity of the tumour boundary
were found. These solutions showed that when tumour consisted of one cell, sensitive cell, the
temporal expansion of the tumour can be followed by tracking a radial change of the tumour boundary.
This was achieved by introducing a local velocity, u(r, t), which described a cellular motion generated
by the balance between tumour cell proliferation and death. An drug resistant sub-population might
arise from mutations of the drug sensitive sub-population via mutations [41,130]. Thus, the derivation
of these solutions served as a key step in comprehending the moving boundary conditions usually
associated with the tumour surface, as well as the roles played by mutations in the evolution of
the drug resistant sub-population. We have shown how the underlying assumptions influence model
analytical solution feasibility. For example, assuming a lower chemotherapeutic drug concentration
and one cell type lead to simplification (via Maclaurin series expansion) of an exponential term,
which described the tumour’s interaction with the chemotherapeutic drug, to a linear term which
helped to attain analytical solutions for the drug and radial velocity of the tumour boundary. These
findings are similar to those obtained by Jackson and Byrne [48]. Numerical solutions of this model
further show the possibility of eradicating sensitive cells when diffusion of chemotherapeutic drug is
a major mode of fluids transport into or out of the tumour. However, the success of the therapy
depends on a low initial number of sensitive cells. Consequently, through the model, we have shown
that early detection of the tumour is important aspect for the efficacious elimination of the tumour,
which is in accordance with findings by [5, 47].
In Chapter 4, sensitivity analysis was used to show that the model was most sensitive to the model
parameters. Specifically, when the drug decay rate was high, there was an increase in the number of
sensitive cell population, and when the external drug influx was increased, there was a corresponding
drop in the number of sensitive cell population. From these observations we concluded that in order to
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efficaciously eliminate the drug sensitive sub-population, it is important to use a chemotherapeutic
drug with a low decay rate, while continuously infusing a drug influx within admissible toxicity
constraints. These results are in accordance to other published findings such as [55, 129, 130, 134].
The numerical solutions for the models showed that it is possible to eradicate the sensitive sub-
population, which, if not removed, could mutate into drug resistant sub-populations. The results
indicate that for the first ODE model with a single drug, complete remission is not feasible, but the
sensitive sub-population is significantly reduced. The reduction of the sensitive sub-population is
slow, thus giving sensitive cell population an opportunity to mutate into a resistant sub-population.
The model was extended to a two drug case where we further considered the effects of genetic point
mutations that confer multi-drug resistance. Mutations have been shown in many studies [5,41,47,51,
52,105,117,125,136] that they contribute significantly to the evolution of drug resistance. This model
showed a significant reduction in the sensitive sub-population. Nevertheless, the persistent growth of
the multi-drug resistant sub-population was unavoidable. Under high genetic point mutations, our
results showed that continuous infusion of the chemotherapeutic drug, within toxicity constraints,
is recommended to reduce the sensitive cell population. Furthermore, our results showed that there
would still be a significant reduction on the number of the tumour sensitive sub-population when the
chemotherapeutic drug with low decay rate was used.
The models presented in this study show how mathematical models may be used to reveal complex
spatial and dynamical interactions between tumours and chemotherapeutic drugs. The interaction of
between tumour cells and chemotherapeutic drugs, subject to drug resistance, has been done in many
studies [5, 9, 42, 47,48,55, 58,59, 102,126]. The preliminary results here expand current knowledge of
mathematical approaches to modelling drug resistance. The results provide a solid foundation of two
compartmental modelling of tumour sub-populations for extending the model to more sophisticated
representation of the biological processes and the chemotherapeutic drug interactions.
The models presented here have significant shortcomings that need to be addressed in order to
make the models suitable for clinical validation. Firstly, the empirically determined parameters, for
example the growth of resistant cells, λR for the first ODE model, and λR1 , λR2 and λR12 for the
second ODE models, need to be sourced from clinical data for the model results to be realistic. Thus,
we have identified a need for more clinical or empirical research in this regard. The second limitation
is that these models only include a tumour in a pre-metastatic state. As discussed in Chapter 1,
when subgroups of cancer cells leave the primary tumour and travel to other distant site in the body
78
and begin to invade a new distant tissue and therein form a new tumour mass, they are said to
have metastasised. Metastasis has been reported as the most frequent cause of cancer death [12–16].
Therefore, because early spread of tumour cells is usually not detected [137], it is important to
prohibit the development of tumour cells prior to metastastic process with the chemotherapeutic
drugs once the tumour is detected. In this regard, these models could possibly be extended to
include the interaction of the tumour and the drug at the secondary site (that is, after the tumour
has metastasised to a new site). This would, however, present a considerable mathematical challenge
because, for instance, such an extension would mean that our first ODE model would consist of six
coupled differential equations that have to be solved simultaneously. Moreover, chemotherapy can
kill tumour cells only at certain stages in the cell cycle, so other tumour cells would be unaffected.
An exciting extension to our work could be to model chemotherapy and immunotherapy concomi-
tantly. Alternatively, it is worth noting that there already exist a number of mathematical models
that combine chemotherapy with immunotherapy [20,26–28,30–32]. Combining immunotherapy with
anti-cancer drugs has the advantage of combating cancerous cells that elude an assault of chemother-
apeutic drugs, and hence result in faster elimination of tumour cell sub-populations. A sophisticated
model of this type was presented in [20] in which the immune system consists of three sub-populations,
namely tumour antigen activated cells, natural killer cells and the circulating lymphocytes (white
blood cells). This model has a great advantage of having already been validated with both mice and
human data.
Our approach would be different from that in [20] and would seek to model the tumour’s interaction
with the drugs, with evolving drug resistance to chemotherapy, but with the enhancement of the
immunotherapy.
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Appendix: Glossary of biological terms
used in this dissertation
Apoptosis programmed cell death.
Detoxification the removal of toxic agents in a living organism.
Differentiation
In developmental biology, differentiation is the term used to denote the cells
developmental capacity to perform a specific function by change of phenotype.
However, in surgical pathology,differentiation, apart from being used as a
classification of whether the tumour is benign of malignant, is used to grade
the degree of tumours capacity in relation to invasiveness and mortality.
Lymphoma
a range of cancers that are associated with the lymphatic system, connecting
network of nodes,organs, and vessels whose primary cell is the lymphocyte.
Malignant
A malignant tumour is the one that is capable of invading the neighbouring
tissues and spreading to other body parts.
In vitro test
A medical trial, experiment or procedure that is usually carried outside the
body of an animal or a patient.
In vivo test A medical trial that is carried inside the body of an animal or a patient.
Metastasize A tumour is said to have metastasized if it has spread to other distant body
parts from the primary tumour site and has began to form a new tumour there.
Mitosis the process of molecular cell division.
Phenotype the set of observable attributes or characteristics of an individual resulting from
mutations in genes when they interact with a surrounding environment.
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Angiogenesis is the formation of new blood vessels from pre-existing blood vessels in the body.
The newly formed blood vessels does not only supply oxygen and nutrients to
cancerous cells, but they also provide an opportunity for tumour cells to get into
blood vessels and spread to other parts of the body.
Proliferate To reproduce/divide/increase in number.
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